[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1227
1. Krentz HB, Kliewer G, Gill MJ: Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med; 2005 Mar;6(2):99-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.
  • OBJECTIVES: To examine changes over a 2-year period in both the mortality rate and the causes of death in a geographically defined HIV-infected population.
  • METHODS: A database search of primary care information for the dates and causes of death for all patients documented with HIV infection and living in Southern Alberta between 1984 and 2003 was undertaken.
  • AIDS deaths were reconciled with Public Health Reports.
  • RESULTS: Between 1984 and 2003, there were 560 deaths in the 1987 individuals living with HIV infection in Southern Alberta.
  • In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era.
  • The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%).
  • The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era.
  • Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths.
  • A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions.
  • Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation.
  • In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
  • CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients.
  • The increasing age of the HIV population, and the increased mean CD4 count, increased proportion of intravenous drug users, increased hepatitis B virus and hepatitis C virus coinfection rate, and increased history of smoking seen in our population also influenced the mortality rate and causes of death.
  • These factors must also be considered in projecting future trends in mortality of an HIV-infected population.
  • [MeSH-major] HIV Infections / mortality
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / mortality. Alberta. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Cause of Death / trends. Disease Progression. Drug Resistance, Multiple, Viral. Humans. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology. Mycobacterium avium-intracellulare Infection / mortality. Mycobacterium avium-intracellulare Infection / virology. Pneumonia, Pneumocystis / mortality. Pneumonia, Pneumocystis / virology. Socioeconomic Factors. Substance Abuse, Intravenous. Treatment Refusal


2. Balderas V, Spechler SJ: Upper gastrointestinal bleeding in a patient with AIDS. Nat Clin Pract Gastroenterol Hepatol; 2006 Jun;3(6):349-53; quiz following 353
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper gastrointestinal bleeding in a patient with AIDS.
  • BACKGROUND: A 38-year-old man with AIDS and hepatitis C was admitted to our hospital in January 2005, with complaints of epigastric pain, odynophagia, and melena of 4 days' duration.
  • DIAGNOSIS: Non-Hodgkin's lymphoma of the stomach (diffuse large B-cell type) with associated gastric ulceration and bleeding.
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Endoscopy, Gastrointestinal. Hemostasis, Endoscopic. Humans. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Male


3. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ, HIV/AIDS Cancer Match Study: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS; 2006 Aug 1;20(12):1645-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in cancer risk among people with AIDS in the United States 1980-2002.
  • BACKGROUND: People with AIDS have heightened cancer risk from immunosuppression.
  • HAART has been available since 1996 and has reduced AIDS-related mortality, but there are few large-scale studies on cancer trends.
  • METHODS: AIDS and cancer registries in 11 US regions (1980-2002) were used to identify cancers in 375 933 people with AIDS.
  • Cancer risk relative to the general population was measured using the standardized incidence ratio (SIR), focusing on the 2 years after AIDS onset for those with AIDS in 1990-1995 and 1996-2002 (HAART era).
  • RESULTS: Between 1990-1995 and 1996-2002, risk declined for the two major AIDS-defining cancers: Kaposi sarcoma [(KS) n = 5131; SIR, 22 100 and 3640, respectively; P < 0.0001] and non-Hodgkin lymphoma [(NHL) n = 3412; SIR, 53.2 and 22.6, respectively; P < 0.0001].
  • Among non-AIDS malignancies, lung cancer was most common, but risk declined between 1990-1995 and 1996-2002 (n = 344; SIR, 3.3 and 2.6, respectively; P = 0.02).
  • Risk of Hodgkin lymphoma increased substantially over the 1990-2002 period (n = 149; SIR, 8.1 and 13.6, respectively; P = 0.003).
  • CONCLUSIONS: Dramatic declines in KS and NHL were temporally related to improving therapies, especially introduction of HAART, but those with AIDS remain at marked risk.
  • Among non-AIDS-related cancers, a recent increase in Hodgkin lymphoma was observed.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Antiretroviral Therapy, Highly Active / adverse effects. Female. Hodgkin Disease / complications. Hodgkin Disease / epidemiology. Hodgkin Disease / immunology. Humans. Incidence. Kidney Neoplasms / complications. Kidney Neoplasms / epidemiology. Kidney Neoplasms / immunology. Lung Neoplasms / complications. Lung Neoplasms / epidemiology. Lung Neoplasms / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged. Risk Factors. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / immunology. Sex Distribution. United States / epidemiology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology


Advertisement
4. Galceran J, Marcos-Gragera R, Soler M, Romaguera A, Ameijide A, Izquierdo A, Borràs J, de Sanjosé S, Casabona J: Cancer incidence in AIDS patients in Catalonia, Spain. Eur J Cancer; 2007 Apr;43(6):1085-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in AIDS patients in Catalonia, Spain.
  • HIV infected people and AIDS patients develop cancer more frequently than the general population.
  • The objective of this study was to evaluate the risk of developing cancer among 15 to 69 year old AIDS patients from two geographic areas: Tarragona and Girona provinces, in north-eastern Spain.
  • We have studied invasive and in situ cancers (for all sites) among 1659 AIDS patients from +/-5 years around the date of their AIDS diagnosis by matching the population-based Cancer Registries with the AIDS Registry covering these populations.
  • For selected types of cancers, SIRs were also calculated for HIV exposure category.
  • Compared with the general population, incidence of cancer among AIDS patients (invasive and in situ) increased 22.9 fold in men (n=142) and 21.0 fold in women (n=45).
  • High statistically significant SIRs were found for Kaposi's sarcoma (KS) (male, 486.4; female, 1030.0), non-Hodgkin's lymphoma (NHL) (male, 126.1; female, 192.8) and invasive cervical cancer (41.8).
  • High risks were also found for Hodgkin's lymphoma (31.1), liver cancer (29.4) and lung cancer (9.4) in men, and in situ cervical cancer (24.4) in women.
  • For all non-AIDS defining malignant neoplasms as a group SIRs were 3.4 in men and 2.5 in women.
  • Among men, homo/bisexuality was strongly related to risk of KS and NHL.
  • The rates of cervical cancer, Hodgkin's lymphoma, liver cancer and lung cancer were among the highest ever reported linked to HIV infection.
  • For the cervical cancer this could be attributable to the low incidence of this cancer in the general population and to the high prevalence of intravenous drug users among HIV women and probably due to poor preventive strategies in this population.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349785.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Nagai H, Odawara T, Ajisawa A, Tanuma J, Hagiwara S, Watanabe T, Uehira T, Uchiumi H, Yotsumoto M, Miyakawa T, Watanabe A, Kambe T, Konishi M, Saito S, Takahama S, Tateyama M, Okada S: Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol; 2010 Jun;84(6):499-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era.
  • Primary central nervous system lymphoma (PCNSL) related to acquired immunodeficiency syndrome (AIDS) is a lethal disorder, but the recent application of highly active antiretroviral therapy (HAART) has significantly improved prognosis.
  • This retrospective cohort study of AIDS-related PCNSL examined the actual clinical outcomes and prognostic variables affecting overall survival (OS) in the HAART era.
  • Twenty-three newly diagnosed AIDS-related PCNSL at 12 regional centre hospitals for HIV/AIDS in Japan between 2002 and 2008 were consecutively enrolled.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Lymphoma, AIDS-Related / radiotherapy

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2010 Sep;85(3):277. Tanuma, Junko [added]
  • (PMID = 20132301.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Kreisl TN, Panageas KS, Elkin EB, Deangelis LM, Abrey LE: Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma; 2008 Sep;49(9):1710-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma.
  • The incidence of human immunodeficiency virus (HIV)-associated primary central nervous system lymphoma (PCNSL) has decreased in the era of highly active anti-retroviral therapy, but PCNSL continues to be a prominent AIDS-defining illness.
  • One hundred and eighty-four patients with both HIV and PCNSL were identified.
  • No time trends in treatment patterns were observed, and no sociodemographic factors were associated with receipt of treatment.
  • Despite improved treatment for both diseases over the past decade, survival remains dismal in this cohort of Medicare/Medicaid beneficiaries with HIV-related PCNSL.
  • These results may not apply to the general HIV population.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma, AIDS-Related / therapy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18661394.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Qi Y, Martin MP, Gao X, Jacobson L, Goedert JJ, Buchbinder S, Kirk GD, O'Brien SJ, Trowsdale J, Carrington M: KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog; 2006 Aug;2(8):e79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIR/HLA pleiotropism: protection against both HIV and opportunistic infections.
  • The compound genotype KIR3DS1/HLA-B Bw4-80I, which presumably favors natural killer cell activation, has been implicated in protection against HIV disease.
  • We show that this genotype confers dual protection over the course of HIV disease; early direct containment of HIV viral load, and late specific defense against opportunistic infections, but not AIDS-related malignancies.
  • The double protection of KIR3DS1/Bw4-80I in an etiologically complex disease such as AIDS, along with the disease specificity of its effects is conceptually novel and underscores the intricacy of host immunogenetics against HIV/AIDS.
  • [MeSH-major] AIDS-Related Opportunistic Infections / genetics. Acquired Immunodeficiency Syndrome / genetics. HLA-B Antigens / genetics. Killer Cells, Natural / immunology. Receptors, Immunologic / genetics
  • [MeSH-minor] Disease Progression. HIV Seropositivity. HIV-1. Humans. Immunocompromised Host. Immunosuppression. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Receptors, KIR. Receptors, KIR3DS1. Sarcoma, Kaposi / genetics. Sarcoma, Kaposi / immunology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2004 Dec 9;432(7018):769-75 [15592417.001]
  • [Cites] JAMA. 1998 Jan 7;279(1):35-40 [9424041.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1069-75 [15809352.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1319-32 [15837816.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1290-2 [16288280.001]
  • [Cites] Int Ophthalmol Clin. 2006 Spring;46(2):91-110 [16770157.001]
  • [Cites] J Infect Dis. 2000 Mar;181(3):872-80 [10720507.001]
  • [Cites] N Engl J Med. 2001 May 31;344(22):1668-75 [11386265.001]
  • [Cites] Curr Opin Immunol. 2001 Aug;13(4):458-64 [11498302.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):429-34 [12134147.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 6;94(21):1592-3 [12419778.001]
  • [Cites] Annu Rev Med. 2003;54:535-51 [12525683.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):781-90 [14523385.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):255-9 [14685277.001]
  • [Cites] N Engl J Med. 1989 Oct 26;321(17):1141-8 [2477702.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Acquir Immune Defic Syndr. 1992;5(5):490-6 [1560346.001]
  • [Cites] Annu Rev Immunol. 1993;11:269-95 [8476562.001]
  • [Cites] AIDS. 1994 Aug;8(8):1123-8 [7986410.001]
  • [Cites] Annu Rev Immunol. 2005;23:225-74 [15771571.001]
  • (PMID = 16933987.001).
  • [ISSN] 1553-7374
  • [Journal-full-title] PLoS pathogens
  • [ISO-abbreviation] PLoS Pathog.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R37 DA004334; United States / NIDA NIH HHS / DA / R56 DA004334; United States / NIDA NIH HHS / DA / R01 DA004334; United States / NIDA NIH HHS / DA / DA04334; United States / Intramural NIH HHS / / ; United Kingdom / Medical Research Council / / G9800943; United States / NCI NIH HHS / CA / N01CO12400; United Kingdom / Medical Research Council / / G0401569; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-B Antigens; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DS1
  • [Other-IDs] NLM/ PMC1550271
  •  go-up   go-down


8. Pantanowitz L, Dezube BJ: Editorial comment: plasmablastic lymphoma--a diagnostic and therapeutic puzzle. AIDS Read; 2007 Sep;17(9):448-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial comment: plasmablastic lymphoma--a diagnostic and therapeutic puzzle.
  • [MeSH-major] HIV Infections / diagnosis. Lymphoma / classification. Mouth Neoplasms / classification

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] AIDS Read. 2007 Sep;17(9):446-7 [17902226.001]
  • (PMID = 17902227.001).
  • [ISSN] 1053-0894
  • [Journal-full-title] The AIDS reader
  • [ISO-abbreviation] AIDS Read
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  •  go-up   go-down


9. Cytokine levels increase risk for non-Hodgkin lymphoma. AIDS Patient Care STDS; 2010 Jun;24(6):395
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine levels increase risk for non-Hodgkin lymphoma.
  • [MeSH-major] Cytokines / blood. HIV Infections / complications. Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin. Risk


10. Louie BE, Harlock J, Hosein A, Miller JD: Laser therapy for an obstructing primary tracheal lymphoma in a patient with AIDS. Can Respir J; 2005 Mar;12(2):86-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laser therapy for an obstructing primary tracheal lymphoma in a patient with AIDS.
  • A patient with AIDS presented with progressive dyspnea leading to respiratory failure with near complete airway obstruction due to primary tracheal lymphoma.
  • [MeSH-major] Airway Obstruction / therapy. Laser Therapy. Lymphoma, AIDS-Related / therapy. Tracheal Neoplasms / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Choking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15785798.001).
  • [ISSN] 1198-2241
  • [Journal-full-title] Canadian respiratory journal
  • [ISO-abbreviation] Can. Respir. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


11. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, Zhao L, Trivedi P, Jones C, Zhang L: Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol; 2007 Jun;81(11):6068-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas.
  • The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected with both Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV).

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5150-63 [12910252.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] Gene. 2003 Oct 16;316:137-41 [14563560.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):46335-42 [15322136.001]
  • [Cites] Int J Cancer. 1977 Jan;19(1):27-33 [188769.001]
  • [Cites] J Virol. 1980 Nov;36(2):506-18 [6253674.001]
  • [Cites] J Virol. 1985 Sep;55(3):710-20 [2991591.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] Virology. 1985 Mar;141(2):221-34 [3002016.001]
  • [Cites] J Virol. 1986 Apr;58(1):233-7 [3005654.001]
  • [Cites] J Gen Virol. 1987 Jun;68 ( Pt 6):1575-86 [2438376.001]
  • [Cites] Virology. 1987 Jul;159(1):161-5 [3037776.001]
  • [Cites] J Virol. 1990 Apr;64(4):1855-8 [2157069.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] J Virol. 1990 May;64(5):2309-18 [2157887.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] J Virol. 1990 Nov;64(11):5441-7 [2170681.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1107-15 [1648447.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] J Virol. 1992 Aug;66(8):5030-9 [1321285.001]
  • [Cites] J Virol. 1993 Aug;67(8):4651-8 [8392605.001]
  • [Cites] J Virol. 1993 Nov;67(11):6768-77 [8411380.001]
  • [Cites] EMBO J. 2000 Jun 15;19(12):3080-9 [10856251.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] J Virol. 2001 Dec;75(24):12393-401 [11711629.001]
  • [Cites] J Virol. 2002 Feb;76(3):998-1003 [11773375.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):437-42 [11752411.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Infect Agents Dis. 1996 Oct;5(4):215-22 [8884366.001]
  • [Cites] J Virol. 1996 Dec;70(12):8653-9 [8970991.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Virology. 1997 Jul 21;234(1):1-13 [9234942.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] EMBO J. 1997 Oct 15;16(20):6131-40 [9359753.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1700-9 [9501091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80 [10591086.001]
  • [Cites] J Virol. 2000 Feb;74(3):1061-8 [10627515.001]
  • [Cites] Leukemia. 2000 Feb;14(2):271-7 [10673744.001]
  • [Cites] J Virol. 2000 Mar;74(6):2550-7 [10684269.001]
  • [Cites] J Biol Chem. 2002 Feb 22;277(8):6438-42 [11741976.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Virol. 1993 Dec;67(12):7648-53 [8230484.001]
  • [Cites] J Virol. 1994 May;68(5):3354-63 [8151794.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1995 Jul;69(7):4390-8 [7769701.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Oct;11(10):1241-5 [8573381.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Leukemia. 1996 Jul;10(7):1237-40 [8684008.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Virology. 1996 Sep 1;223(1):29-40 [8806537.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3216-23 [10082588.001]
  • [Cites] J Virol. 1999 Jul;73(7):5556-67 [10364304.001]
  • [Cites] J Virol. 1999 Sep;73(9):7271-7 [10438815.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(23):12987-95 [15542650.001]
  • [Cites] J Virol. 2004 Dec;78(23):13028-36 [15542654.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Nov;79(22):14383-91 [16254372.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9163-9 [16469740.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Nat Med. 2002 Jun;8(6):594-9 [12042810.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] BMC Microbiol. 2002 Jul 23;2:20 [12137568.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Virology. 2002 Aug 1;299(2):301-14 [12202233.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6337-44 [12414666.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] J Virol. 2003 Jan;77(2):1441-51 [12502859.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1905-12 [12411306.001]
  • [Cites] J Virol. 2003 Mar;77(6):3809-15 [12610155.001]
  • [Cites] J Virol. 2003 Apr;77(8):5000-7 [12663807.001]
  • (PMID = 17376914.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI060547; United States / NCI NIH HHS / CA / R01 CA108951; United States / NIAID NIH HHS / AI / R21AI59132; United States / NIAID NIH HHS / AI / R21 AI059132; United States / NCRR NIH HHS / RR / P20RR15635; United States / NIAID NIH HHS / AI / U54 AI057160; United States / NCRR NIH HHS / RR / P20 RR015635; United States / NCI NIH HHS / CA / R01CA108951
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1900272
  •  go-up   go-down


12. Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali S, Yephthomi T, Pradeep A, Saghayam S, Flanigan T, Mayer KH, Solomon S: Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India. Int J Infect Dis; 2010 Feb;14(2):e127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India.
  • OBJECTIVE: To describe the causes of mortality among the HIV-infected in southern India in the era of highly active antiretroviral therapy (HAART).
  • METHODS: Analyses of this patient cohort were conducted using the YRG Centre for AIDS Research and Education HIV Natural History Observational Database.
  • Close to three-fourths of patients (70%) died from an AIDS-defining illness (ADI).
  • Three patients (4%) died from non-Hodgkin lymphoma.
  • CONCLUSIONS: AIDS-related events continue to be the major source of mortality among the HIV-infected in southern India in the era of HAART.
  • This mortality pattern justifies increased proactive efforts to identify HIV-infected patients and initiate HAART earlier, before patients present to care with advanced immunodeficiency.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19632872.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069432; United States / NIAID NIH HHS / AI / U01 AI 069432
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


13. Simonelli C, Tedeschi R, Gloghini A, Talamini R, Bortolin MT, Berretta M, Spina M, Morassut S, Vaccher E, De Paoli P, Carbone A, Tirelli U: Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection. J Med Virol; 2009 May;81(5):888-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infection.
  • This is a mono-institutional analysis of the clinical features, immunological and virological findings, and prognostic factors of patients with HIV infection and HHV-8-lymphoproliferative disorders.
  • Patients with Multicentric Castleman Disease and HHV-8-related lymphoma diagnosed and treated from April 1987 to June 2004 were included in the study.
  • HHV-8 and HIV plasma viral load, CD4+ count, hematologic parameters, and general wellbeing (performance status) were assessed at the onset of the diseases and analyzed in order to identify possible prognostic factors.
  • Nine patients with Multicentric Castleman disease, and 16 with HHV-8-related lymphomas (13 primary effusion lymphomas and 3 solid lymphomas), were diagnosed and treated out of 327 HIV-related non-Hodgkin's lymphomas.
  • Four patients with Multicentric Castleman disease received only antiretroviral drugs; 5 HAART plus oral etoposide.
  • Nine patients with primary effusion lymphoma were treated with a CHOP-like regimen (Cyclophosphamide, Prednisone anthracyclines, Vinca alkaloids, Bleomycin, Etoposide) and HAART; 1 with etoposide and HAART, 1 with HAART alone.
  • The patients with solid lymphoma underwent CHOP-like chemotherapy.
  • Patients with Multicentric Castleman disease showed lower median values of HHV-8 viral load and longer overall survival compared with HHV-8-related lymphomas.
  • In the univariate analysis, HHV-8-related lymphoma, HHV-8 viral load >40,000 cp/ml and performance status >2 were associated with an increased risk of death.
  • Multivariate analysis confirmed the diagnosis of lymphoma as an independent predictor of shorter survival.
  • [MeSH-major] HIV Infections / complications. Herpesviridae Infections / complications. Herpesvirus 8, Human / physiology. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / complications. Viral Load
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. DNA, Viral / blood. Female. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / diagnosis. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / virology. Humans. Lymphoma / complications. Lymphoma / diagnosis. Lymphoma / drug therapy. Lymphoma / virology. Lymphoma, Primary Effusion / complications. Lymphoma, Primary Effusion / diagnosis. Lymphoma, Primary Effusion / drug therapy. Lymphoma, Primary Effusion / virology. Male. Middle Aged. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome. Young Adult


14. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant; 2008 Jan;14(1):59-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
  • Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients.
  • High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in sustained complete remissions in selected patients with recurrent chemosensitive disease.
  • Based on a favorable experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-HIV-associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken using the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent HIV-associated NHL and HL.
  • One patient died on day +33 posttransplantation from hepatic veno-occlusive disease (VOD) and multiorgan failure.
  • No other fatal regimen-related toxicity occurred.
  • This multi-institutional trial demonstrates that a regimen of dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT is well tolerated and is associated with favorable disease-free survival (DFS) and OS probabilities for selected patients with HIV-associated NHL and HL.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18158962.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01 CA070047; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083035; United States / NCI NIH HHS / CA / U01 CA083118; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / R01 CA095423; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / U01CA083035; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  • [Other-IDs] NLM/ NIHMS281894; NLM/ PMC4524737
  •  go-up   go-down


15. Rajkumar SV: Multiple myeloma. Curr Probl Cancer; 2009 Jan-Feb;33(1):7-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 1;61(9):3535-40 [11325813.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):172-9 [11328297.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):209-16 [11360893.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1951-2 [11419443.001]
  • [Cites] J Cell Biochem. 2001 Apr 2-27;82(1):110-22 [11400168.001]
  • [Cites] Blood. 2001 Jul 15;98(2):492-4 [11435324.001]
  • [Cites] Br J Haematol. 2001 Jun;113(4):1020-34 [11442498.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1274-6 [11480571.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1614-5 [11520815.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Aug;57(5):365-76 [11599654.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5611-22 [11607813.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):607-12 [11740818.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):613-9 [11740819.001]
  • [Cites] Blood. 2002 Feb 1;99(3):731-5 [11806971.001]
  • [Cites] Oncologist. 2002;7(1):9-16 [11854543.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] Clin Chem. 2002;48(4):655-7 [11901068.001]
  • [Cites] Am J Med. 2002 Apr 1;112(5):412-3 [11904117.001]
  • [Cites] Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92 [11943931.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1715-7 [12393501.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):489-91 [12583950.001]
  • [Cites] Haematologica. 2003 Feb;88(2):176-85 [12604407.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2496-506 [12456500.001]
  • [Cites] Nat Struct Biol. 2000 Nov;7(11):999-1001 [11062549.001]
  • [Cites] Leukemia. 2003 Apr;17(4):775-9 [12682636.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Nat Cell Biol. 1999 Aug;1(4):221-6 [10559920.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1249-57 [10626148.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1295-314, xi [10626152.001]
  • [Cites] Invest New Drugs. 2000 May;18(2):109-21 [10857991.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2037-44 [10979944.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):972-3 [11012329.001]
  • [Cites] Mayo Clin Proc. 2000 Sep;75(9):897-901 [10994824.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3719-28 [10999766.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17(11):1921-5 [12412796.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):16-9 [12506164.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):21-33 [12528874.001]
  • [Cites] Mayo Clin Proc. 2003 Jan;78(1):34-9 [12528875.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1 Suppl):21-30 [12546384.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1786-90 [15756000.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4532-9 [15731182.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Jul 1;106(1):35-9 [15761019.001]
  • [Cites] N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 [16000365.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4662-8 [16034042.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2156-61 [15920009.001]
  • [Cites] Mayo Clin Proc. 2005 Oct;80(10):1371-82 [16212152.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3755-9 [16105975.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:340-5 [16304401.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4050-3 [16118317.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9227-33 [16275936.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):431-6 [16365178.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):929-36 [16432076.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):945-52 [16484704.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1021-30 [16525139.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3131-6 [9787148.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1777-82 [12685831.001]
  • [Cites] Br J Haematol. 2003 May;121(3):411-8 [12716363.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):110-5 [12720118.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2):169-71 [12720130.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):293-304 [12732167.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):768-71 [12780791.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):78-84 [12823348.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Br J Haematol. 2003 Aug;122(4):607-16 [12899716.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3759-64 [12881316.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3469-70 [12893762.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4444-54 [14645435.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1546-58 [14989251.001]
  • [Cites] Hematol J. 2004;5(2):112-7 [15048060.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Biochemistry. 1990 Nov 13;29(45):10289-97 [2175651.001]
  • [Cites] S Afr Med J. 1991 Jan 19;79(2):65-7 [1989088.001]
  • [Cites] Teratology. 1992 Nov;46(5):417-8 [1462245.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3382-7 [8507875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Mayo Clin Proc. 1994 Sep;69(9):895-902 [8065197.001]
  • [Cites] Arch Intern Med. 1994 Sep 12;154(17):1935-44 [8074597.001]
  • [Cites] Cell. 1994 Oct 7;79(1):13-21 [7923371.001]
  • [Cites] Nat Struct Biol. 2000 Nov;7(11):1062-7 [11062564.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3880-6 [11090073.001]
  • [Cites] Acta Oncol. 2000;39(7):843-7 [11145443.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1035-44 [11167737.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):558-67 [11208851.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1566-71 [11238092.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Mar;2(3):179-87 [11265247.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1191-200 [11283917.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3071-6 [11306489.001]
  • [Cites] Blood. 2001 May 1;97(9):2900-2 [11313287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93 [11316563.001]
  • [Cites] Transplant Proc. 1988 Apr;20(2 Suppl 2):226-8 [3284069.001]
  • [Cites] Lancet. 1988 Sep 3;2(8610):568 [2900947.001]
  • [Cites] Teratology. 1988 Sep;38(3):203-15 [3067415.001]
  • [Cites] BMJ. 1989 Feb 18;298(6671):432 [2495052.001]
  • [Cites] Arch Intern Med. 1990 Apr;150(4):863-9 [2183734.001]
  • [Cites] N Engl J Med. 2007 Mar 15;356(11):1110-20 [17360989.001]
  • [Cites] Br J Haematol. 2007 Jul;138(2):176-85 [17593024.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3892-901 [17679727.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4459-65 [17785703.001]
  • [Cites] Lancet. 2007 Oct 6;370(9594):1209-18 [17920916.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1805-10 [17875806.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2171-7 [18362366.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1588-95 [18683218.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3107-14 [18505783.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3591-3 [18612103.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):653-9 [19036082.001]
  • [Cites] EMBO J. 1994 Nov 15;13(22):5433-41 [7957109.001]
  • [Cites] Chirality. 1995;7(1):44-52 [7702998.001]
  • [Cites] Science. 1995 Apr 28;268(5210):533-9 [7725097.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2354-60 [7666094.001]
  • [Cites] J Intensive Care Med. 1995 May-Jun;10(3):128-41 [10155178.001]
  • [Cites] Arch Intern Med. 1995 Oct 23;155(19):2069-74 [7575066.001]
  • [Cites] Stem Cells. 1995 Aug;13 Suppl 2:56-63 [8520513.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3915-21 [7579361.001]
  • [Cites] J Biol Chem. 1995 Dec 8;270(49):29447-52 [7493983.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2115-8 [8609725.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Am J Med. 1996 Jun;100(6):624-8 [8678082.001]
  • [Cites] Annu Rev Biochem. 1996;65:801-47 [8811196.001]
  • [Cites] AIDS. 1996 Nov;10(13):1501-7 [8931784.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):855-60 [9023346.001]
  • [Cites] Blood. 1997 Feb 1;89(3):789-93 [9028309.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13437-45 [9148969.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2659-66 [9215838.001]
  • [Cites] Exp Eye Res. 1997 Jun;64(6):971-8 [9301478.001]
  • [Cites] Trends Biochem Sci. 1997 Oct;22(10):383-7 [9357313.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2501-7 [9516151.001]
  • [Cites] Br J Cancer. 1998 Apr;77(7):1103-7 [9569046.001]
  • [Cites] Am J Hematol. 1998 Jun;58(2):142-4 [9625583.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4342-8 [9766662.001]
  • [Cites] Bone Marrow Transplant. 1998 Nov;22(9):835-43 [9827810.001]
  • [Cites] Hematol J. 2002;3(1):43-8 [11960395.001]
  • [Cites] Leukemia. 2002 Apr;16(4):433-43 [11960320.001]
  • [Cites] Blood. 2002 May 1;99(9):3163-8 [11964279.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):175-87 [11990854.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2210-6 [12114422.001]
  • [Cites] Curr Opin Chem Biol. 2002 Aug;6(4):493-500 [12133726.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1168-71 [12149193.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1417-24 [12149226.001]
  • [Cites] Clin Exp Immunol. 2002 Aug;129(2):247-53 [12165080.001]
  • [Cites] Mayo Clin Proc. 2002 Aug;77(8):813-22 [12173715.001]
  • [Cites] Clin Chem. 2002 Sep;48(9):1437-44 [12194920.001]
  • [Cites] Br J Haematol. 2002 Sep;118(4):1041-7 [12199783.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3719-36 [12202673.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4996-5000 [12208752.001]
  • [Cites] Blood Rev. 2002 Dec;16(4):245-53 [12350367.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Curr Opin Oncol. 2002 Nov;14(6):628-34 [12409653.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4319-23 [12409330.001]
  • [Cites] Lancet. 2006 Mar 11;367(9513):825-31 [16530576.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1362-9 [16571879.001]
  • [Cites] Blood. 2006 May 1;107(9):3474-80 [16397129.001]
  • [Cites] Mayo Clin Proc. 2006 May;81(5):693-703 [16706268.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1138-44 [16617319.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1130-7 [16628189.001]
  • [Cites] Leukemia. 2006 Jun;20(6):937-8 [16721383.001]
  • [Cites] Haematologica. 2006 Jul;91(7):968-71 [16757414.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1047-53 [16901028.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1100-3 [16901034.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1467-73 [16855634.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):573-89 [16938117.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2165-72 [16772605.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1498-505 [17043025.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3289-94 [16873668.001]
  • [Cites] Mayo Clin Proc. 2006 Dec;81(12):1575-8 [17165636.001]
  • [Cites] Leukemia. 2007 Jan;21(1):164-8 [17096015.001]
  • [Cites] Leukemia. 2007 Jan;21(1):151-7 [17096017.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Mayo Clin Proc. 2007 Mar;82(3):323-41 [17352369.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] Cell Death Differ. 1998 Dec;5(12):1062-75 [9894613.001]
  • [Cites] Bone Marrow Transplant. 1999 Feb;23(3):221-6 [10084252.001]
  • [Cites] Clin Ther. 1999 Feb;21(2):319-30 [10211535.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2615-22 [10363983.001]
  • [Cites] Bone Marrow Transplant. 1999 Jun;23(12):1267-72 [10414914.001]
  • [Cites] Drug Saf. 1999 Sep;21(3):161-9 [10487395.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2638-45 [10499643.001]
  • [Cites] Biochim Biophys Acta. 1953 Jan;10(1):193-4 [13041735.001]
  • [Cites] N Engl J Med. 1957 Sep 12;257(11):491-6 [13464965.001]
  • [Cites] Cancer Chemother Rep. 1962 Aug;21:87-99 [13867794.001]
  • [Cites] Harvey Lect. 1960-1961;56:211-31 [14004528.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3052-7 [15265788.001]
  • [Cites] Cancer. 1956 Mar-Apr;9(2):262-72 [13304841.001]
  • [Cites] Cancer Chemother Rep. 1962 Feb;16:257-9 [14470881.001]
  • [Cites] J Immunol. 1964 Mar;92:431-4 [14128988.001]
  • [Cites] Clin Pharmacol Ther. 1965 May-Jun;6:292-7 [14296025.001]
  • [Cites] Clin Pharmacol Ther. 1965 May-Jun;6:298-302 [14296026.001]
  • [Cites] Clin Pharmacol Ther. 1965 May-Jun;6:303-6 [14296027.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2667-74 [15481060.001]
  • [Cites] Leukemia. 2005 Feb;19(2):191-4 [15538406.001]
  • [Cites] Leukemia. 2005 Mar;19(3):449-55 [15674420.001]
  • [Cites] J Bone Miner Res. 2005 Mar;20(3):487-93 [15746994.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] Haematologica. 2004 Jul;89(7):826-31 [15257934.001]
  • [Cites] J Support Oncol. 2003 Sep-Oct;1(3):194-205 [15334875.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1879-82 [15385925.001]
  • [Cites] N Engl J Med. 2004 Oct 28;351(18):1860-73 [15509819.001]
  • [Cites] Blood. 1966 Mar;27(3):328-42 [5933438.001]
  • [Cites] Cancer Chemother Rep. 1967 Jun;51(3):179-87 [6043738.001]
  • [Cites] Lancet. 1967 Dec 23;2(7530):1354-6 [4170040.001]
  • [Cites] JAMA. 1969 Jun 2;208(9):1680-5 [5818682.001]
  • [Cites] Bull World Health Organ. 1971;45(6):719-32 [4947831.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Arch Dermatol. 1979 May;115(5):636-7 [443847.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Med Pediatr Oncol. 1985;13(5):239-43 [4033539.001]
  • [Cites] Ann Intern Med. 1986 Jul;105(1):8-11 [3717812.001]
  • [Cites] N Engl J Med. 1987 Jul 16;317(3):170-1 [3600707.001]
  • [Cites] Lancet. 1988 Jan 16;1(8577):117 [2891954.001]
  • [Cites] Lancet. 1988 Feb 13;1(8581):359 [2893167.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):827 [2895345.001]
  • (PMID = 19254626.001).
  • [ISSN] 1535-6345
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA062242-130011; United States / NCI NIH HHS / CA / R01 CA107476-05; United States / NCI NIH HHS / CA / P01 CA062242; United States / NCI NIH HHS / CA / CA107476-05; United States / NCI NIH HHS / CA / CA062242-130011; United States / NCI NIH HHS / CA / R01 CA107476
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 291
  • [Other-IDs] NLM/ NIHMS103008; NLM/ PMC2743983
  •  go-up   go-down


16. Dewan MZ, Uchihara JN, Terashima K, Honda M, Sata T, Ito M, Fujii N, Uozumi K, Tsukasaki K, Tomonaga M, Kubuki Y, Okayama A, Toi M, Mori N, Yamamoto N: Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood; 2006 Jan 15;107(2):716-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir.
  • Adult T-cell leukemia (ATL), an aggressive malignancy of CD4+ T cells associated with human T-cell leukemia virus type I (HTLV-I) infection, carries a very poor prognosis because of the resistance of leukemic cells to any conventional regimen, including chemotherapy.
  • We examined the effect of ritonavir, an HIV protease inhibitor, on HTLV-I-infected T-cell lines and primary ATL cells and found that it induced apoptosis and inhibited transcriptional activation of NF-kappaB in these cells.
  • In nonobese diabetic/severe combined immunodeficient (NOD/SCID)/gammacnull (NOG) mice, ritonavir very efficiently prevented tumor growth and leukemic infiltration in various organs of NOG mice at the same dose used for treatment of patients with AIDS.
  • [MeSH-major] Apoptosis / drug effects. HIV Protease Inhibitors / pharmacology. NF-kappa B / metabolism. Neoplasms, Experimental. Ritonavir / pharmacology. Transcription, Genetic / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cyclin D2. Cyclins / metabolism. Disease Models, Animal. Female. Human T-lymphotropic virus 1 / physiology. Humans. Inhibitor of Apoptosis Proteins. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Mice. Mice, Inbred NOD. Mice, SCID. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-myc / metabolism. bcl-X Protein / metabolism

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16174765.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / CCND2 protein, human; 0 / Cyclin D2; 0 / Cyclins; 0 / HIV Protease Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / MYC protein, human; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-X Protein; O3J8G9O825 / Ritonavir
  •  go-up   go-down


17. De Socio GV, Simonetti S, Rosignoli D, Minga P, Tomassini GM, Baldelli F: Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma. Int J STD AIDS; 2008 Oct;19(10):715-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma.
  • We describe a 42-year-old man with AIDS and Hodgkin's lymphoma whose severe and recalcitrant cutaneous warts resolved following treatment with local 1% cidofovir.
  • In advanced HIV disease complicated by additional haematological malignancy, cutaneous warts may be difficult to treat and present a challenge for the attending physicians.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. HIV Infections / complications. Hodgkin Disease / complications. Lymphoma, AIDS-Related / complications. Organophosphonates / administration & dosage. Warts / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Warts.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824628.001).
  • [ISSN] 0956-4624
  • [Journal-full-title] International journal of STD & AIDS
  • [ISO-abbreviation] Int J STD AIDS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


18. Bielen D, Mortelé K, Peters H, Lombard D, Ros R: Small bowel obstruction secondary to disseminated candidiasis in an immunocompromised patient: radiologic-pathologic correlation. JBR-BTR; 2005 Jan-Feb;88(1):20-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIDS, leukemia), is increasingly encountered in daily medical practice.
  • We report on a case of a 33-year-old immunocompromised woman with a history of recurrent T-cell lymphoblastic lymphoma, which presented with abdominal pain.
  • [MeSH-minor] Adult. Enteritis / microbiology. Fatal Outcome. Female. Humans. Lymphoma, T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792164.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


19. Othman N, Yip CW, Intan HI, Zainuddin Z, Amran F: An abdominal mass owing to Penicillium marneffei in an HIV-infected 7-year-old boy: case report. Ann Trop Paediatr; 2006 Sep;26(3):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An abdominal mass owing to Penicillium marneffei in an HIV-infected 7-year-old boy: case report.
  • A 7-year-old boy, referred with lymphoma, presented with prolonged fever and intra-abdominal lymphadenopathy demonstrated on computed tomography (CT) of the abdomen.
  • The patient was subsequently proven serologically to be positive for human immunodeficiency virus (HIV).
  • A high level of clinical suspicion and awareness is necessary for early diagnosis of penicilliosis, especially in an era of an increasing prevalence of HIV in this region.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Mycoses / diagnosis. Penicillium

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925966.001).
  • [ISSN] 0272-4936
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Genebat M, Ruiz-Mateos E, Pulido I, González-Serna A, García-Pergañeda A, Méndez G, Romero-Sánchez MC, Ferrando-Martínez S, Leal M: Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practice. Curr HIV Res; 2010 Sep;8(6):482-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: to analyze the long-term immunovirological effect and tolerability of a maraviroc-containing antiretroviral therapy in viraemic and pretreated HIV-infected patients with a high prevalence of hepatitis C virus (HCV) coinfection.
  • METHODS: forty-six R5 HIV-infected patients (48% HCV-coinfected) started a maraviroc-containing antiretroviral regimen, including patients with multidrug resistant virus and patients after first virologic failure.
  • One patient developed a non-Hodgkin lymphoma after 36 weeks follow up, despite undetectable viral load and significant CD4+ increase was achieved (the only AIDS-defining event observed).
  • CONCLUSIONS: maraviroc-containing regimen is long-term effective and well tolerated in HIV-infected patients in routine clinical practice and in different clinical scenarios.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Anti-Retroviral Agents / therapeutic use. Cyclohexanes / therapeutic use. HIV Infections / drug therapy. Hepatitis C, Chronic / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Female. HIV Protease Inhibitors / therapeutic use. HIV-1 / drug effects. Humans. Male. Middle Aged. Pyrrolidinones / therapeutic use. Raltegravir Potassium. Retrospective Studies. Spain. Time. Viral Load


21. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.
  • Epstein-Barr virus (EBV) has been associated with BL with different frequencies depending on the clinical variant.
  • Kaposi sarcoma-associated herpesvirus, or human herpesvirus 8 (HHV-8), infects a wide range of normal cells, having a well-established role in the pathogenesis of various neoplasms, including Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease (MCD) and MCD-associated plasmablastic lymphoma.
  • In secondary immunodeficiencies, such as HIV-1 infection and organ transplantation, HHV-8 is considered an opportunistic pathogen linked to the development of lymphomas in patients with AIDS and HIV + patients.
  • We found no association of BL with HHV-8 in EBV + BL or in EBV-cases, including the HIV + BL group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


22. Honda M, Morikawa T, Yamaguchi Y, Tani M, Yamaguchi K, Iijima K, Akishita M, Fukayama M, Ouchi Y: [A case of a primary effusion lymphoma in the elderly]. Nihon Ronen Igakkai Zasshi; 2009;46(6):551-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a primary effusion lymphoma in the elderly].
  • We report a 90-year-old man who was given a diagnosis of pleural effusion lymphoma (PEL) based on the detailed immunochemical and DNA analyses of the pleural effusion.
  • He was bed-ridden and on enteral nutrition due to severe Alzheimer's disease, and also had diabetes mellitus.
  • Most of the atypical cells were CD30 positive, with human herpes virus-8 (HHV-8)-associated protein.
  • PEL is a rare type of lymphoma confined to the body cavities without any prominent tumor mass, and its pathogenesis is related to HHV-8 infection.
  • PEL develops mostly in immunocompromised patients, such as those with AIDS.
  • [MeSH-major] Lymphoma, Primary Effusion / diagnosis

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139653.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Epstein JB, Cabay RJ, Glick M: Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Nov;100(5):571-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral malignancies in HIV disease: changes in disease presentation, increasing understanding of molecular pathogenesis, and current management.
  • Infection with human immunodeficiency virus (HIV) and progression to acquired immune deficiency syndrome (AIDS) are associated with a vide variety of morbidities.
  • Local and systemic diseases can develop in association with HIV infection and may manifest themselves as malignancies of the oropharynx.
  • Advances in HIV management, fueled by increasing understanding of molecular pathogenesis, have resulted in marked changes in the prevalence of oral malignant disease.
  • This paper discusses recent trends in the presentation and treatment of malignancies related to HIV and AIDS with an emphasis on malignancies seen in the oral cavity.
  • [MeSH-major] HIV Infections / complications. Mouth Neoplasms / complications
  • [MeSH-minor] Animals. Antiretroviral Therapy, Highly Active. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Developed Countries. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Lymphoma, AIDS-Related / therapy. Prevalence. Sarcoma, Kaposi / complications. Sarcoma, Kaposi / epidemiology. Sarcoma, Kaposi / therapy. United States / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243242.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Number-of-references] 82
  •  go-up   go-down


24. Shiels MS, Cole SR, Wegner S, Armenian H, Chmiel JS, Ganesan A, Marconi VC, Martinez-Maza O, Martinson J, Weintrob A, Jacobson LP, Crum-Cianflone NF: Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr; 2008 Aug 1;48(4):485-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.
  • OBJECTIVE: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events.
  • DESIGN: Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427).
  • METHODS: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks.
  • RESULTS: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006.
  • The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort.
  • The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events.
  • CONCLUSIONS: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 2002 Oct;31(5):951-8 [12435766.001]
  • [Cites] Epidemiology. 2000 Sep;11(5):550-60 [10955408.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):22-9 [12853195.001]
  • [Cites] Am J Epidemiol. 2003 Oct 1;158(7):687-94 [14507605.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1267-74 [14575971.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 [15158046.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1070-6 [15265968.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Biometrics. 1986 Mar;42(1):121-30 [3719049.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Stat Med. 1994 Oct 15-30;13(19-20):2127-39 [7846415.001]
  • [Cites] Biometrics. 1995 Jun;51(2):524-32 [7662841.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):65-70 [10534148.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Am J Epidemiol. 2000 Nov 15;152(10):923-33 [11092434.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] AIDS. 2001 Feb 16;15(3):347-55 [11273215.001]
  • [Cites] J Infect. 2001 Feb;42(2):134-9 [11531320.001]
  • [Cites] Am J Epidemiol. 2001 Oct 1;154(7):675-81 [11581102.001]
  • [Cites] J Epidemiol Community Health. 2002 Feb;56(2):153-9 [11812817.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7 [12048367.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 May 1;30(1):111-8 [12048371.001]
  • [Cites] N Engl J Med. 1997 Sep 11;337(11):725-33 [9287227.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):543-9 [9492772.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] JAMA. 1998 Nov 4;280(17):1497-503 [9809730.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] AIDS. 1999 Oct 1;13(14):1933-42 [10513653.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):378-84 [16054937.001]
  • [Cites] AIDS. 2005 Nov 18;19(17):2009-18 [16260908.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):194-200 [16394852.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):310-5 [16371516.001]
  • [Cites] AIDS. 2006 Jul 13;20(11):1531-8 [16847408.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] HIV Med. 2006 Sep;7(6):369-77 [16903981.001]
  • [Cites] Stat Med. 2007 May 20;26(11):2389-430 [17031868.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):142-4 [12455069.001]
  • (PMID = 18614916.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042-11; United States / NIAID NIH HHS / AI / HU0001-05-2-0011; United States / NIAID NIH HHS / AI / AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NIDDK NIH HHS / DK / U01 DK066116; United States / NIAID NIH HHS / AI / AI035039-16; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / U01 AI035041-17; United States / NIAID NIH HHS / AI / UO1-AI-37984; United States / NIAID NIH HHS / AI / U01 AI035040-16; United States / NCI NIH HHS / CA / T32 CA009314-27S1; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / U01 AI035039-17; United States / NIAID NIH HHS / AI / AI037984-08; United States / NIAID NIH HHS / AI / U01 AI035043-11; United States / NIAID NIH HHS / AI / AI035039-17; United States / NIAID NIH HHS / AI / AI035043-10; United States / NIAID NIH HHS / AI / U01 AI035042-17; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NIAID NIH HHS / AI / U01 AI037613-08; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NIAID NIH HHS / AI / AI035042-17; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / U01 AI037984-08; United States / NCI NIH HHS / CA / T32 CA009314-28S3; United States / PHS HHS / / HU0001-05-2-0011; None / None / / M01 RR000722-23; United States / NCI NIH HHS / CA / CA009314-26S1; United States / NIAID NIH HHS / AI / U01 AI035039-16; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / AI037613-08; United States / NIAID NIH HHS / AI / U01 AI035041-10; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NCRR NIH HHS / RR / 5-MO1-RR-00722; United States / NCRR NIH HHS / RR / M01 RR000722-23; United States / NIAID NIH HHS / AI / U01 AI035043-10; United States / NCI NIH HHS / CA / T32 CA009314-26S1; United States / NCI NIH HHS / CA / CA009314-28S3; United States / NIAID NIH HHS / AI / U01 AI035039; United States / NIAID NIH HHS / AI / UO1-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NCI NIH HHS / CA / T32 CA009314
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ NIHMS165363; NLM/ PMC2805176
  •  go-up   go-down


25. Fulco PP, Hynicka L, Rackley D: Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother; 2010 Feb;44(2):377-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raltegravir-based HAART regimen in a patient with large B-cell lymphoma.
  • OBJECTIVE: To describe the antiretroviral management of a patient diagnosed simultaneously with HIV/AIDS and diffuse large B-cell lymphoma, focusing on the drug-drug interactions between highly active antiretroviral therapy (HAART) and concomitant cancer chemotherapy.
  • CASE SUMMARY: A 55-year-old white man was recently diagnosed with HIV/AIDS and presented 1 month later with complaints of nausea, vomiting, abdominal pain, double vision, right eye discomfort/swelling, and a 3.6-kg weight loss.
  • An excisional biopsy of a right inguinal lymph node confirmed a new diagnosis of diffuse large B-cell lymphoma.
  • DISCUSSION: HAART improves the chemotherapeutic response in patients with HIV and lymphoma.
  • [MeSH-minor] Antiretroviral Therapy, Highly Active / methods. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Drug Interactions. HIV Integrase Inhibitors / therapeutic use. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / therapeutic use. Raltegravir Potassium. Vincristine / therapeutic use


26. Contreras-Galindo R, Kaplan MH, Leissner P, Verjat T, Ferlenghi I, Bagnoli F, Giusti F, Dosik MH, Hayes DF, Gitlin SD, Markovitz DM: Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol; 2008 Oct;82(19):9329-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer.
  • Here we show that RNA from human endogenous retrovirus K (HERV-K) (HML-2), a relatively recent entrant into the human genome, can be found in very high titers in the plasma of patients with lymphomas and breast cancer as measured by either reverse transcriptase PCR or nucleic acid sequence-based amplification.
  • Finally, using immunoelectron microscopy, we show the presence of HERV-K (HML-2) virus-like particles in the plasma of lymphoma patients.
  • [MeSH-major] Breast Neoplasms / virology. Endogenous Retroviruses / genetics. Lymphoma / virology. RNA, Viral / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Iodixanol .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol Methods. 2006 Sep;136(1-2):51-7 [16678919.001]
  • [Cites] Genome Res. 2008 Mar;18(3):343-58 [18256243.001]
  • [Cites] Genome Res. 2006 Dec;16(12):1548-56 [17077319.001]
  • [Cites] PLoS Pathog. 2007 Jan;3(1):e10 [17257061.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):205-6 [11752294.001]
  • [Cites] Leukemia. 2002 Feb;16(2):254-9 [11840292.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1800-7 [12060620.001]
  • [Cites] Biol Reprod. 2003 Feb;68(2):651-4 [12533431.001]
  • [Cites] Mol Pathol. 2003 Feb;56(1):11-8 [12560456.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1528-35 [12629516.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8735-41 [14695188.001]
  • [Cites] Virology. 2004 Apr 25;322(1):190-8 [15063128.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4894-9 [15044706.001]
  • [Cites] Virus Res. 2004 Aug;104(1):11-6 [15177887.001]
  • [Cites] Exp Hematol. 2004 Jun;32(6):520-5 [15183892.001]
  • [Cites] J Virol. 2004 Oct;78(19):10310-9 [15367597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14572-9 [15310846.001]
  • [Cites] J Virol. 1986 Nov;60(2):589-98 [3021993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4480-4 [8506289.001]
  • [Cites] Virology. 1993 Sep;196(1):349-53 [8356806.001]
  • [Cites] J Gen Virol. 1994 Jul;75 ( Pt 7):1755-60 [7517432.001]
  • [Cites] Cancer Lett. 1995 Mar 23;90(1):3-11 [7720040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 28;93(11):5177-84 [8643549.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13404-8 [10557333.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4328-36 [10980608.001]
  • [Cites] J Gen Virol. 2001 Mar;82(Pt 3):591-6 [11172100.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Genomics. 2001 Mar 1;72(2):137-44 [11401426.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1553-60 [11410490.001]
  • [Cites] Mol Cells. 2001 Aug 31;12(1):137-41 [11561724.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1531-5 [11591322.001]
  • [Cites] Ann Neurol. 2001 Oct;50(4):434-42 [11601494.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S261-7 [8797733.001]
  • [Cites] Virology. 1996 Aug 15;222(2):451-6 [8806530.001]
  • [Cites] Pancreas. 1998 Jul;17(1):89-97 [9667526.001]
  • [Cites] J Virol. 1998 Oct;72(10):8384-91 [9733890.001]
  • [Cites] Curr Biol. 1999 Aug 26;9(16):861-8 [10469592.001]
  • [Cites] J R Soc Med. 2004 Dec;97(12):560-5 [15574851.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Nov;20(11):1223-9 [15588344.001]
  • [Cites] Arch Virol. 2005 Jan;150(1):177-84 [15449135.001]
  • [Cites] J Gen Virol. 2005 Mar;86(Pt 3):783-7 [15722540.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3223-8 [15735668.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4172-80 [15899808.001]
  • [Cites] Genomics. 2005 Sep;86(3):337-41 [16024218.001]
  • [Cites] J Virol. 2005 Oct;79(19):12507-14 [16160178.001]
  • [Cites] J Virol. 2005 Oct;79(19):12592-6 [16160187.001]
  • [Cites] J Virol. 2005 Dec;79(24):15573-7 [16306628.001]
  • [Cites] Melanoma Res. 2006 Jun;16(3):223-34 [16718269.001]
  • [Cites] Nature. 2006 Jul 6;442(7098):79-81 [16823453.001]
  • [Cites] J Virol. 2007 Jun;81(11):5607-16 [17360752.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1723-7 [17409210.001]
  • [Cites] Trends Genet. 2007 Jul;23(7):326-33 [17524519.001]
  • [Cites] AIDS. 2007 Nov 30;21(18):2417-24 [18025878.001]
  • [Cites] PLoS Pathog. 2007 Nov;3(11):e165 [17997601.001]
  • [Cites] Virology. 2008 Feb 5;371(1):216-25 [18076964.001]
  • [Cites] J Gen Virol. 2008 Feb;89(Pt 2):567-72 [18198388.001]
  • [Cites] J Virol. 2008 Feb;82(3):1622-5 [18045933.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Oct;22(10):979-84 [17067267.001]
  • (PMID = 18632860.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI062248; United States / NIAID NIH HHS / AI / R01 AI062248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / RNA, Viral; 0 / Triiodobenzoic Acids; 92339-11-2 / iodixanol
  • [Other-IDs] NLM/ PMC2546968
  •  go-up   go-down


27. Li HJ, Gao YQ, Cheng JL, Zhang YZ: Diagnostic imaging, preautopsy imaging and autopsy findings of. Chin Med J (Engl); 2009 Sep 20;122(18):2142-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Aquired immune deficiency syndrome (AIDS) presents a challenge to medical researchers because of its unique pathological and clinical picture.
  • The clinical data, particularly autopsy evidence, from China have failed to provide enough pathological and etiological evidence for AIDS diagnosis, which impairs the reliability of the diagnosis and our full understanding of the occurrence and development of AIDS complications.
  • The purpose of this study was to investigate the imaging and pathologic characteristics of AIDS.
  • METHODS: Autopsy, imaging and pathological data from 8 cases of AIDS were retrospectively analyzed.
  • RESULTS: The autopsy data indicated the presence of parasitic infections, bacterial infections, fungal infections, and virus infections in AIDS patients.
  • Pneumocystis pneumonia, pulmonary tuberculosis, coccobacteria pneumonia, Aspergillus pneumonia, cytomegalovirus pneumonia, toxoplasma encephalitis, lymphoma and cerebrovascular diseases were found in these patients.
  • CONCLUSIONS: During the course of AIDS progression, the concurrent multiple infections as well as tumor development may result in multiple organ pathological changes and clinically complex symptoms that further complicate the imaging and pathological manifestations, thus resulting in difficult differential diagnosis.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781300.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


28. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H: Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol; 2008 Jul;9(7):683-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However cancer is a common disease in Africa with 650 000 people, of a population of 965 million, diagnosed annually.
  • The cancers with the highest incidence are cervical, breast, and now HIV-associated Kaposi's sarcoma.
  • The top five cancers in males--Kaposi's sarcoma (constituting 12.9% of all cancers in males) and cancer of the liver (14.8%), prostate (9.5%), bladder (6.1%), and non-Hodgkin lymphoma (5.7%)--and in females--cancer of the cervix (constituting 23.3% of all cancers in females) and breast (19.2%), Kaposi's sarcoma (5.1%), cancer of the liver (5.0%), and non-Hodgkin lymphoma (3.7%)--are discussed in detail.
  • The cancer burden in Africa is likely to increase as a result of increases in HIV-associated cancers, changes in lifestyles associated with economic development, and the increasing age of the population (despite AIDS).

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18598933.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


29. Khandekar MM, Deshmukh SD, Holla VV, Rane SR, Kakrani AL, Sangale SA, Habbu AA, Pandit DP, Bhore AV, Sastry J, Phadke MA, Bollinger RC: Profile of bone marrow examination in HIV/AIDS patients to detect opportunistic infections, especially tuberculosis. Indian J Pathol Microbiol; 2005 Jan;48(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of bone marrow examination in HIV/AIDS patients to detect opportunistic infections, especially tuberculosis.
  • Morphological evaluation of 140 bone marrow aspirations received in haematopathology laboratory with serologically established HIV infection, along with other relevant special haematological tests, was done during 1st Jan 1999 - 31st Dec 2002 at state government run tertiary care General Hospital in Maharashtra state, India.
  • One patient had immunoblastic lymphoma and showed bone marrow infiltration.
  • Findings in this study strongly indicate that in HIV/AIDS, AFB stain should be done on each marrow aspirate to rule out tuberculosis in countries like India; where TB and AIDS are marching together.
  • [MeSH-major] AIDS-Related Opportunistic Infections / diagnosis. Bone Marrow / microbiology. Bone Marrow Examination. HIV Infections / complications. Mycobacterium tuberculosis / isolation & purification. Tuberculosis / diagnosis


30. Porcellini E, Carbone I, Ianni M, Licastro F: Alzheimer's disease gene signature says: beware of brain viral infections. Immun Ageing; 2010;7:16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alzheimer's disease gene signature says: beware of brain viral infections.
  • BACKGROUND: Recent findings from a genome wide association investigation in a large cohort of patients with Alzheimer's disease (AD) and non demented controls (CTR) showed that a limited set of genes was in a strong association (p > l0-5) with the disease.
  • PRESENTATION OF THE HYPOTHESIS: In this report we suggest that the polymorphism association in 8 of these genes is consistent with a non conventional interpretation of AD etiology.Nectin-2 (NC-2), apolipoprotein E (APOE), glycoprotein carcinoembryonic antigen related cell adhesion molecule- 16 (CEACAM-16), B-cell lymphoma-3 (Bcl-3), translocase of outer mitochondrial membrane 40 homolog (T0MM-40), complement receptor-1 (CR-l), APOJ or clusterin and C-type lectin domain A family-16 member (CLEC-16A) result in a genetic signature that might affect individual brain susceptibility to infection by herpes virus family during aging, leading to neuronal loss, inflammation and amyloid deposition.
  • IMPLICATIONS OF THE HYPOTHESIS: We hypothesized that such genetic trait may predispose to AD via complex and diverse mechanisms each contributing to an increase of individual susceptibility to brain viral infections.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Lipid Res. 2009 Feb;50(2):183-92 [18787236.001]
  • [Cites] Exp Eye Res. 2008 Aug;87(2):122-30 [18572164.001]
  • [Cites] J Virol. 2009 May;83(9):4678-89 [19225003.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1088-93 [19734902.001]
  • [Cites] Nat Genet. 2009 Oct;41(10):1094-9 [19734903.001]
  • [Cites] PLoS One. 2010;5(3):e9505 [20209079.001]
  • [Cites] JAMA. 2010 May 12;303(18):1832-40 [20460622.001]
  • [Cites] Neurosci Lett. 2010 Oct 11;483(2):96-100 [20674675.001]
  • [Cites] Hum Genet. 1986 Jan;72(1):9-14 [3002957.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6096-110 [8947032.001]
  • [Cites] Stroke. 2003 Sep;34(9):2126-31 [12920256.001]
  • [Cites] Expert Rev Mol Med. 2003 May;5(15):1-19 [14585169.001]
  • [Cites] Aging Cell. 2003 Dec;2(6):305-18 [14677633.001]
  • [Cites] J Med Virol. 2004 Aug;73(4):605-11 [15221907.001]
  • [Cites] Acta Virol. 2005;49(1):45-9 [15929398.001]
  • [Cites] J Am Geriatr Soc. 2006 Jul;54(7):1046-54 [16866674.001]
  • [Cites] EMBO Rep. 2007 Feb;8(2):188-93 [17186027.001]
  • [Cites] Exp Gerontol. 2007 Jun;42(6):563-70 [17337145.001]
  • [Cites] Neurosci Lett. 2007 Dec 18;429(2-3):95-100 [17980964.001]
  • [Cites] Neurochem Int. 2008 May;52(6):920-34 [18164103.001]
  • [Cites] Oncogene. 2008 Jun 12;27(26):3721-8 [18278069.001]
  • [Cites] J Alzheimers Dis. 2008 May;13(4):393-405 [18487848.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8718-23 [18562290.001]
  • [Cites] Sex Transm Infect. 2008 Dec;84(7):516-7 [18708484.001]
  • [Cites] J Pathol. 2009 Jan;217(1):131-8 [18973185.001]
  • [Cites] Genomics. 2009 May;93(5):441-8 [19442637.001]
  • [Cites] PLoS Pathog. 2009 May;5(5):e1000442 [19461877.001]
  • [Cites] Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):409-17 [19554612.001]
  • [Cites] Arch Neurol. 2010 Dec;67(12):1473-84 [20697030.001]
  • [Cites] J Virol. 2000 Feb;74(4):1931-8 [10644366.001]
  • [Cites] Microsc Res Tech. 2000 Aug 15;50(4):305-15 [10936885.001]
  • [Cites] Electrophoresis. 2001 Feb;22(3):445-8 [11258753.001]
  • [Cites] Science. 2002 Jul 19;297(5580):353-6 [12130773.001]
  • [Cites] Hepatology. 2002 Aug;36(2):456-63 [12143056.001]
  • [Cites] J Cell Sci. 2003 Jan 1;116(Pt 1):17-27 [12456712.001]
  • [Cites] J Virol. 2003 May;77(9):5360-9 [12692238.001]
  • [Cites] Cell Microbiol. 2004 May;6(5):401-10 [15056211.001]
  • [Cites] AIDS. 2005 Mar 4;19(4):407-11 [15750394.001]
  • [Cites] J Virol. 2006 Jun;80(11):5383-7 [16699018.001]
  • [Cites] Aging Cell. 2007 Dec;6(6):841-2 [17725689.001]
  • [Cites] J Virol. 2009 Mar;83(6):2601-10 [19129438.001]
  • (PMID = 21156047.001).
  • [ISSN] 1742-4933
  • [Journal-full-title] Immunity & ageing : I & A
  • [ISO-abbreviation] Immun Ageing
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3019140
  •  go-up   go-down


31. Danilov AV, Pilichowska M, Danilova OV, Sprague KA: AIDS-related Burkitt lymphoma--a heterogeneous disease? Leuk Res; 2008 Dec;32(12):1939-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt lymphoma--a heterogeneous disease?
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis. Submandibular Gland Neoplasms / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18472158.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


32. Clayton G, Omasta-Martin A, Bower M: The effects of HAART on AIDS-related Kaposi's sarcoma and non-Hodgkin's lymphoma. J HIV Ther; 2006 Sep;11(3):51-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of HAART on AIDS-related Kaposi's sarcoma and non-Hodgkin's lymphoma.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / epidemiology


33. Goldstein MA, Naidich TP, Silverman ME: Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical importance of delayed MRI contrast enhancement of primary central nervous system lymphoma in AIDS.
  • Accurately distinguishing between cerebral toxoplasmosis and primary central nervous system lymphoma (PCNSL), still the most common secondary CNS mass lesion complications of AIDS, has long represented a diagnostic challenge in those with HIV.
  • A young adult male with AIDS presented with evolving ophthalmoplegias, Parinaud's syndrome and gait dysfunction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Apr;24(4):554-5 [12695179.001]
  • [Cites] Neurology. 1998 Jan;50(1):21-6 [9443452.001]
  • (PMID = 21686485.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027744
  •  go-up   go-down


34. Mallouk A, Pham PT, Pham PC: Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies. Clin Exp Nephrol; 2006 Dec;10(4):284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent FSGS and Hodgkin's lymphoma: case report and literature review on the link between nephrotic glomerulopathies and hematological malignancies.
  • In solid tumors, the NS is most often due to membranous glomerulonephropathy, whereas in common hematological malignancies, minimal-change disease predominates.
  • Focal segmental glomerulosclerosis (FSGS) is among the least frequently reported renal lesion associated with malignancy.
  • METHODS: We report a case of the simultaneous diagnoses of FSGS and Hodgkin's lymphoma, and review the literature on various nephrotic glomerulonephropathies associated with common leukemia and lymphoma.
  • Nephrotic glomerulonephropathies have also been well documented among patients with lymphomas, in particular, Hodgkin's lymphoma.
  • While minimal-change disease is most commonly found in association with Hodgkin's lymphoma, more diverse and complex renal lesions are associated with non-Hodgkin's lymphoma.
  • [MeSH-major] Glomerulosclerosis, Focal Segmental / complications. Hodgkin Disease / complications
  • [MeSH-minor] Adult. Glomerulonephritis / etiology. Humans. Leukemia / complications. Lymphoma / complications. Male. Nephrotic Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nephrol. 1986 Dec;26(6):311-3 [3802598.001]
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi45-51 [12953042.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):362-74 [15129648.001]
  • [Cites] Am J Kidney Dis. 1998 Nov;32(5):785-93 [9820448.001]
  • [Cites] Scand J Work Environ Health. 1985;11 Suppl 1:83-90 [3906873.001]
  • [Cites] Lancet. 1974 Sep 7;2(7880):556-60 [4140273.001]
  • [Cites] Leuk Lymphoma. 2002 Nov;43(11):2083-92 [12533032.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • [Cites] Mayo Clin Proc. 1983 Sep;58(9):568-77 [6887974.001]
  • [Cites] Am J Kidney Dis. 1994 Jun;23(6):773-83 [8203357.001]
  • [Cites] Postgrad Med J. 1988 May;64(751):395-7 [3200784.001]
  • [Cites] Kidney Int. 1992 Jul;42(1):127-35 [1635342.001]
  • [Cites] AIDS Patient Care STDS. 1998 Aug;12(8):605-9 [15468431.001]
  • [Cites] Br Med J. 1922 Dec 23;2(3234):1201-1208.2 [20770949.001]
  • [Cites] J Pathol. 2002 Aug;197(5):677-83 [12210089.001]
  • [Cites] J Clin Pathol. 1995 Feb;48(2):160-3 [7745117.001]
  • [Cites] South Med J. 1989 Sep;82(9):1187-9 [2772690.001]
  • [Cites] N Engl J Med. 1983 Apr 14;308(15):888-96 [6835286.001]
  • [Cites] Ann Intern Med. 1966 Jan;64(1):41-51 [5900782.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14 [10561025.001]
  • [Cites] Rev Clin Exp Hematol. 2000 Mar;4(1):5-21 [11491097.001]
  • [Cites] Nephrology (Carlton). 2004 Dec;9(6):387-91 [15663641.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4):631-57 [14520615.001]
  • [Cites] Am J Kidney Dis. 2005 Aug;46(2):278-82 [16112046.001]
  • [Cites] Am J Nephrol. 1983 Jul-Aug;3(4):228-32 [6688503.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 May;23(5):743-6 [8172220.001]
  • [Cites] Ann Intern Med. 1994 Nov 15;121(10):818 [7944068.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):874-5 [4016678.001]
  • [Cites] Oncogene. 1999 Oct 28;18(44):5982-90 [10557087.001]
  • (PMID = 17186334.001).
  • [ISSN] 1342-1751
  • [Journal-full-title] Clinical and experimental nephrology
  • [ISO-abbreviation] Clin. Exp. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 31
  •  go-up   go-down


35. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma; 2006 Sep;47(9):1872-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
  • The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.
  • This was a retrospective, multi-center cohort study of all HIV-1-infected patients diagnosed with BL/BLL between 1990 - 2004.
  • In a multi-variable Cox regression analysis, treatment according to the GMALL protocol was significantly associated with prolonged survival with a relative hazard rate of 0.13 (95% CI 0.03 - 0.63, P = 0.01).
  • In conclusion, the short and intensive GMALL protocol for B-ALL/NHL is feasible in patients with AIDS-BL/BLL.
  • In the era of HAART, more intensive chemotherapy regimens should be considered in patients with highly aggressive lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065000.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


36. Suzuki K, Nakazato T, Sanada Y, Mihara A, Tachikawa N, Kurai H, Yoshimura Y, Hayashi H, Yoshida S, Kakimoto T: [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma]. Rinsho Ketsueki; 2010 Mar;51(3):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment with hyper-CVAD and highly active anti-retroviral therapy (HAART) for AIDS-related Burkitt lymphoma].
  • He was diagnosed as HIV positive.
  • Colonoscopy was performed and histological examination of the colon tumor revealed Burkitt's lymphoma (BL).
  • In the HAART era, the survival of patients with AIDS-related diffuse large cell lymphoma (DLCL) improved dramatically, whereas the survival of similarly treated patients with AIDS-related BL remained poor.
  • Our case suggests that intensive chemotherapy with hyper-CVAD/MTX-Ara-C combined with HAART may be well tolerated and effective in AIDS-related BL.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Colonic Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379116.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; EPOCH protocol
  •  go-up   go-down


37. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


38. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery. Infect Agent Cancer; 2007;2:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The AIDS and Cancer Specimen Resource: role in HIV/AIDS scientific discovery.
  • The AIDS Cancer and Specimen Resource (ACSR) supports scientific discovery in the area of HIV/AIDS-associated malignancies.
  • The ACSR was established as a cooperative agreement between the NCI (Office of the Director, Division of Cancer Treatment and Diagnosis) and regional consortia, University of California, San Francisco (West Coast), George Washington University (East Coast) and Ohio State University (Mid-Region) to collect, preserve and disperse HIV-related tissues and biologic fluids and controls along with clinical data to qualified investigators.
  • The ACSR tissue bank has more than 100,000 human HIV positive specimens that represent different processing (43), specimen (15), and anatomical site (50) types.
  • Requests have been greatest for Kaposi's sarcoma (32%) and non-Hodgkin's lymphoma (26%).
  • ACSR also provides tissue microarrays of, e.g., Kaposi's sarcoma and non-Hodgkin's lymphoma, for biomarker assays and has developed collaborations with other groups that provide access to additional AIDS-related malignancy specimens.
  • The ACSR promotes the scientific exploration of the relationship between HIV/AIDS and malignancy by participation at national and international scientific meetings, contact with investigators who have productive research in this area and identifying, collecting, preserving, enhancing, and dispersing HIV/AIDS-related malignancy specimens to funded, approved researchers at no fee.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Res. 2003 Oct 15;60(1):108-18 [14522412.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2004;50 Online Pub:OL581-9 [15555424.001]
  • [Cites] Pediatr Infect Dis J. 2005 Mar;24(3):237-42 [15750460.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:12 [15871741.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 Oct;289(4):H1373-80 [15923317.001]
  • [Cites] Science. 2005 Jun 10;308(5728):1582-3 [15947174.001]
  • [Cites] BMC Med Inform Decis Mak. 2005;5:25 [16086837.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):3-11 [16867895.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1599-601 [10942415.001]
  • [Cites] Nat Med. 2001 Jan;7(1):73-9 [11135619.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):733-41 [12428794.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] BMC Med Inform Decis Mak. 2003 May 23;3:5 [12769826.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Blood. 1996 Dec 15;88(12):4620-9 [8977254.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Jan 20;13(2):135-49 [9007199.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • (PMID = 17335575.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA066531
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1851770
  •  go-up   go-down


39. Fukumoto R, Andresen V, Bialuk I, Cecchinato V, Walser JC, Valeri VW, Nauroth JM, Gessain A, Nicot C, Franchini G: In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. Blood; 2009 Apr 16;113(16):3726-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein.
  • The human T-cell leukemia/lymphoma virus type 1 (HTLV-1) ORF-I encodes a 99-amino acid hydrophobic membrane protein, p12(I), that affects receptors in different cellular compartments.
  • Genetic analysis of ORF-I from ex vivo samples of HTLV-1-infected patients reveals predominant amino acid substitutions within ORF-I that affect proteolytic cleavage, suggesting that ER-associated functions of p12(I) may contribute to the survival and proliferation of the infected T cells in the host.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] J Virol. 2007 Sep;81(18):9707-17 [17609265.001]
  • [Cites] Virology. 2000 Aug 15;274(1):86-93 [10936091.001]
  • [Cites] J Virol. 2001 Jul;75(13):6086-94 [11390610.001]
  • [Cites] J Virol. 2001 Aug;75(16):7672-82 [11462039.001]
  • [Cites] Blood. 2001 Aug 1;98(3):823-9 [11468184.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):248-59 [11803468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):899-902 [12230932.001]
  • [Cites] J Virol. 2002 Oct;76(20):10374-82 [12239314.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3625-30 [12824381.001]
  • [Cites] J Virol. 2003 Oct;77(20):11027-39 [14512551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] AIDS Res Hum Retroviruses. 1992 Nov;8(11):1845-9 [1489573.001]
  • [Cites] J Virol. 1993 Apr;67(4):2360-6 [8445734.001]
  • [Cites] J Virol. 1993 Dec;67(12):7701-4 [8230493.001]
  • [Cites] Virus Res. 1993 Dec;30(3):317-34 [8109163.001]
  • [Cites] Virology. 1994 Nov 1;204(2):656-64 [7941334.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):701-6 [7860146.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3619-39 [7579327.001]
  • [Cites] Int J Cancer. 1995 Nov 15;63(4):494-9 [7591256.001]
  • [Cites] J Virol. 1996 Jun;70(6):3599-605 [8648694.001]
  • [Cites] J Virol. 1998 May;72(5):4408-12 [9557732.001]
  • [Cites] J Virol. 1999 Aug;73(8):6460-7 [10400740.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Oct;20(10):1092-9 [15585100.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jun;21(6):580-2 [15989464.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] J Immunol. 2006 May 1;176(9):5463-70 [16622014.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 May;22(5):466-9 [16706625.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] J Virol. 2007 Sep;81(17):9088-99 [17582004.001]
  • [Cites] Trends Genet. 2000 Jun;16(6):276-7 [10827456.001]
  • (PMID = 18791162.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115398; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calreticulin; 0 / Histocompatibility Antigens Class I; 0 / IL2RB protein, human; 0 / IL2RG protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / Interleukin-2 Receptor beta Subunit; 0 / Membrane Proteins; 0 / Protein Sorting Signals; 0 / Receptors, Antigen, T-Cell; 0 / Viral Regulatory and Accessory Proteins; 0 / p12I protein, Human T-lymphotropic virus 1; 139873-08-8 / Calnexin
  • [Other-IDs] NLM/ PMC2670790
  •  go-up   go-down


40. Lu C, Zeng Y, Huang Z, Huang L, Qian C, Tang G, Qin D: Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus. Am J Pathol; 2005 Jan;166(1):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-8) is a gamma-herpesvirus consistently identified in Kaposi's sarcoma (KS), primary effusion lymphoma, and multicentric Castleman's disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2002 Aug;126(8):941-6 [12171492.001]
  • [Cites] J Virol. 2003 Nov;77(21):11425-35 [14557628.001]
  • [Cites] Int J Cancer. 1980 Jul 15;26(1):23-9 [6263803.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):693-700 [6283973.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6333-8 [3022918.001]
  • [Cites] Lancet. 1987 Aug 15;2(8555):390 [2886840.001]
  • [Cites] Cell. 1999 Dec 23;99(7):817-27 [10619434.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):743-9 [10702388.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1961-71 [10854219.001]
  • [Cites] J Clin Microbiol. 2000 Aug;38(8):3055-60 [10921977.001]
  • [Cites] Jpn J Infect Dis. 2000 Aug;53(4):137-55 [11056556.001]
  • [Cites] J Virol. 2001 Feb;75(3):1378-86 [11152511.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13427-32 [11154704.001]
  • [Cites] Virology. 2002 Jun 5;297(2):270-80 [12083825.001]
  • [Cites] Lancet. 1987 Aug 15;2(8555):390-2 [2886841.001]
  • [Cites] Science. 1989 Jan 13;243(4888):223-6 [2643161.001]
  • [Cites] Biotechniques. 1988 Mar;6(3):196-7, 199-200 [2483319.001]
  • [Cites] J Infect Dis. 1990 Apr;161(4):680-4 [2156943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5922-6 [1648234.001]
  • [Cites] Adv Exp Med Biol. 1991;303:27-38 [1805571.001]
  • [Cites] Immunol Rev. 1992 Jun;127:147-55 [1506004.001]
  • [Cites] Curr Opin Oncol. 1992 Oct;4(5):867-74 [1457502.001]
  • [Cites] Lancet. 1993 May 15;341(8855):1288-9 [8098435.001]
  • [Cites] J Virol. 1993 Nov;67(11):6768-77 [8411380.001]
  • [Cites] Virology. 1994 Mar;199(2):311-22 [8122364.001]
  • [Cites] J Infect Dis. 1994 Jul;170(1):211-5 [8014502.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Virology. 1995 Aug 20;211(2):544-53 [7645258.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] J Med Virol. 1995 Jul;46(3):189-93 [7561788.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Arthritis Rheum. 1995 Dec;38(12):1735-7 [8849344.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Int J Cancer. 1996 Jun 11;66(6):717-22 [8647638.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):283-8 [8691144.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Biochem Mol Med. 1996 Jun;58(1):1-12 [8809339.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] AIDS. 1996;10 Suppl A:S51-7 [8883610.001]
  • [Cites] J Virol. 1996 Nov;70(11):8151-4 [8892944.001]
  • [Cites] Eur J Cancer Prev. 1996 Oct;5(5):410-2 [8972281.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):163-71 [8988896.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] Lancet. 1997 Mar 15;349(9054):774-5 [9074581.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):68-71 [9212225.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Virology. 1998 Jan 5;240(1):118-26 [9448696.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):1001-4 [9736049.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Hum Virol. 1998 Mar-Apr;1(3):193-9 [10195242.001]
  • [Cites] N Engl J Med. 1999 Jun 17;340(24):1863-71 [10369849.001]
  • [Cites] J Virol. 1999 Jul;73(7):5894-902 [10364341.001]
  • [Cites] Virology. 1999 Sep 15;262(1):237-49 [10489357.001]
  • [Cites] J Infect Dis. 1995 Feb;171(2):273-80 [7844362.001]
  • [Cites] Verh Dtsch Ges Pathol. 1994;78:260-4 [7533997.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1723-34 [7535796.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1043-4 [7723505.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):914-9 [7635454.001]
  • (PMID = 15632010.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1602294
  •  go-up   go-down


41. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI: HIV infection and the risk of cancers with and without a known infectious cause. AIDS; 2009 Nov 13;23(17):2337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and the risk of cancers with and without a known infectious cause.
  • OBJECTIVE: To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons.
  • METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).
  • RESULTS: We identified 20 277 HIV-infected and 202 313 HIV-uninfected persons.
  • HIV-infected persons experienced 552 ADC, 221 infection-related NADC, and 388 infection-unrelated NADC.
  • HIV-uninfected persons experienced 179 ADC, 284 infection-related NADC, and 3418 infection-unrelated NADC.
  • The rate ratio comparing HIV-infected and HIV-uninfected persons for ADC was 37.7 [95% confidence interval (CI): 31.7-44.8], with decreases in the rate ratio over time (P < 0.001).
  • The rate ratio for infection-related NADC was 9.2 (95% CI: 7.7-11.1), also with decreases in the rate ratio over time (P < 0.001).
  • These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.
  • Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.
  • CONCLUSION: In comparison with those without HIV infection, HIV-infected persons are at particular risk for cancers with a known infectious cause, although the higher risk has decreased in the antiretroviral therapy era.
  • Cancers without a known infectious cause are modestly increased in HIV-infected persons compared with HIV-uninfected persons.


42. Verma N, Chaudhary UB, Costa LJ, Gudena V, Lazarchick J: Primary testicular lymphoma and AIDS. Ann Clin Lab Sci; 2010;40(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular lymphoma and AIDS.
  • Immunosuppressed patients have an increased risk for developing extranodal lymphoma, including testicular lymphoma.
  • In AIDS patients, primary testicular lymphoma has been reported as an initial manifestation of the disease.
  • These patients typically present at an early age; their lymphomas usually have aggressive histologic appearance and are associated with poor prognosis.
  • We report a testicular lymphoma consistent with diffuse large B-cell lymphoma (DLBCL) in an AIDS patient and we review the literature on primary testicular lymphoma in AIDS patients.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / pathology


43. Zhang YJ, Wang KY, Stein DA, Patel D, Watkins R, Moulton HM, Iversen PL, Matson DO: Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antiviral Res; 2007 Jan;73(1):12-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with Kaposi's sarcoma and primary effusion lymphoma (PEL).
  • The KSHV replication and transcription activator (RTA) and latency-associated nuclear antigen (LANA) play key roles in activating KSHV lytic replication and maintaining KSHV latency, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Cell. 1995 Apr 21;81(2):179-83 [7736570.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):187-95 [9212909.001]
  • [Cites] J Virol. 1997 Aug;71(8):5915-21 [9223481.001]
  • [Cites] AIDS. 1997 Sep;11(11):1327-32 [9302441.001]
  • [Cites] J Virol. 2005 Aug;79(15):9665-76 [16014928.001]
  • [Cites] Bioconjug Chem. 2005 Jul-Aug;16(4):959-66 [16029037.001]
  • [Cites] J Gen Virol. 2005 Nov;86(Pt 11):3081-90 [16227231.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 10;1489(1):141-58 [10807004.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2000 Jun;10(3):163-76 [10905553.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2000 Aug;10(4):263-74 [10984120.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):216-20 [11017081.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Virol. 2001 Jan;75(1):458-68 [11119614.001]
  • [Cites] Genome Biol. 2001;2(5):REVIEWS1015 [11387041.001]
  • [Cites] Genesis. 2001 Jul;30(3):94-102 [11477682.001]
  • [Cites] Genesis. 2001 Jul;30(3):129-33 [11477690.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):317-25 [11763348.001]
  • [Cites] J Virol. 2002 May;76(10):5208-19 [11967335.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] Front Biosci. 2002 Jun 1;7:d1439-53 [12045008.001]
  • [Cites] J Virol. 2002 Oct;76(20):10320-31 [12239308.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2003 Feb;13(1):31-43 [12691534.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] Hepatology. 2003 Aug;38(2):503-8 [12883495.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3897-900 [12904413.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):290-9 [15025524.001]
  • [Cites] J Virol. 2004 Jun;78(11):5891-9 [15140987.001]
  • [Cites] J Virol. 2004 Jun;78(12):6585-94 [15163750.001]
  • [Cites] J Virol. 2004 Jul;78(13):7248-56 [15194800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9073-8 [15184661.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] J Virol. 2004 Oct;78(20):11121-9 [15452232.001]
  • [Cites] Biomedicine. 1975 Jul;22(4):276-84 [179629.001]
  • [Cites] Adv Exp Med Biol. 1991;303:27-38 [1805571.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Oncogene. 1997 Oct 16;15(16):1979-85 [9365244.001]
  • [Cites] J Virol. 1998 Jan;72(1):701-7 [9420276.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] Nucleic Acids Symp Ser. 1997;(36):29-32 [9478197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21783-9 [10419493.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] J Virol. 2005 Apr;79(8):4599-609 [15795246.001]
  • [Cites] J Virol. 2005 Apr;79(8):5116-28 [15795296.001]
  • (PMID = 16842866.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103612-02; United States / NCI NIH HHS / CA / R21 CA103612-02; United States / NCI NIH HHS / CA / R21 CA103612-01A2; United States / NCI NIH HHS / CA / CA103612-03; United States / NCI NIH HHS / CA / CA103612-01A2; United States / NCI NIH HHS / CA / CA-103612; United States / NCI NIH HHS / CA / R21 CA103612; United States / NCI NIH HHS / CA / R21 CA103612-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Immediate-Early Proteins; 0 / Morpholines; 0 / Morpholinos; 0 / Nuclear Proteins; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 0 / latency-associated nuclear antigen
  • [Other-IDs] NLM/ NIHMS44954; NLM/ PMC2390898
  •  go-up   go-down


44. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.
  • BACKGROUND: The relative roles of immunodeficiency, HIV viral load, and combination antiretroviral therapy (cART) in the onset of individual cancers have rarely been examined.
  • We examined the effect of these factors on the risk of specific cancers in patients infected with HIV-1.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • The risk of Kaposi's sarcoma and non-Hodgkin lymphoma increased for current plasma HIV RNA greater than 100 000 copies per mL compared with patients with controlled viral load (RR 3.1, 95% CI 2.3-4.2, p<0.0001; and 2.9, 2.1-3.9, p<0.0001, respectively), whereas cART was independently associated with a decreased incidence (0.3, 0.2-0.4, p<0.0001; and 0.8, 0.6-1.0, p=0.07, respectively).
  • INTERPRETATION: cART would be most beneficial if it restores or maintains CD4 count above 500 cells per microL, thereby indicating an earlier diagnosis of HIV infection and an earlier treatment initiation.
  • Cancer-specific screening programmes need to be assessed in patients with HIV.
  • FUNDING: Agence Nationale de Recherches sur le SIDA et les hépatites (ANRS), INSERM, and the French Ministry of Health.
  • [MeSH-major] Anti-HIV Agents / administration & dosage. HIV Infections / complications. Neoplasms / etiology


45. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver AIDS-related lympoma.
  • Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • Ultrasonography and computed tomography scans may be helpful in the diagnosis of focal hepatic lymphoma.
  • Image-guided fine-needle biopsy with histopathology of the liver lesions is the gold standard for the diagnosis of hepatic lymphoma.
  • We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


46. O'Hara AJ, Vahrson W, Dittmer DP: Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma. Blood; 2008 Feb 15;111(4):2347-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma.
  • Using real-time quantitative polymerase chain reaction (QPCR)-based arrays, we determined changes in gene copy number, pre-miRNA, and mature miRNA levels for the largest set of primary effusion lymphomas (PELs) to date.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1454-61 [12424116.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):415-9 [14508493.001]
  • [Cites] Science. 2004 Jan 2;303(5654):83-6 [14657504.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):e43 [14985473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genes Dev. 2004 Mar 1;18(5):504-11 [15014042.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1511-8 [15070997.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] Mol Cell. 2004 Jul 23;15(2):185-97 [15260970.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):343-9 [15372041.001]
  • [Cites] Methods Mol Biol. 2005;292:449-80 [15507725.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] Nat Methods. 2005 Apr;2(4):269-76 [15782219.001]
  • [Cites] Nucleic Acids Res. 2005;33(8):2697-706 [15891114.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Nucleic Acids Res. 2005;33(17):5394-403 [16192569.001]
  • [Cites] Nucleic Acids Res. 2005;33(21):e182 [16314296.001]
  • [Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41 [16754881.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Dec;171(2):119-21 [17116491.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11590-3 [17178851.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1046-54 [17149698.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):293-6 [10749213.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jun;124(6):824-6 [10835513.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] J Infect Dis. 2007 Mar 1;195(5):645-59 [17262705.001]
  • [Cites] Oncogene. 2007 May 31;26(26):3769-76 [17173072.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5017-22 [17297439.001]
  • [Cites] Nat Biotechnol. 2007 Sep;25(9):996-7 [17846629.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • (PMID = 18079361.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2234063
  •  go-up   go-down


47. Sarkar C, Sharma MC, Deb P, Singh R, Santosh V, Shankar SK: Primary central nervous system lymphoma--a hospital based study of incidence and clinicopathological features from India (1980-2003). J Neurooncol; 2005 Jan;71(2):199-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma--a hospital based study of incidence and clinicopathological features from India (1980-2003).
  • All the cases occurred in immunocompetent patients, except one case of HIV positive at NIMHANS, and one case of renal transplant at AIIMS.
  • Majority of the cases were diffuse, high grade, large cell lymphoma, B-cell immunophenotype.
  • The association of PCNSL with HIV/AIDS has been low in India, possibly due to early death in AIDS on account of opportunistic infections.
  • [MeSH-major] Central Nervous System Neoplasms / epidemiology. Central Nervous System Neoplasms / pathology. Lymphoma / epidemiology. Lymphoma / pathology

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Dec 1;62(11):2461-5 [3179963.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):675-9 [8627644.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10 (5):1125-34 [8880200.001]
  • [Cites] J Neurooncol. 1994;19(3):197-215 [7807171.001]
  • [Cites] Ann Oncol. 1999 Jan;10(1):65-70 [10076724.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):890 [8826824.001]
  • [Cites] Leuk Lymphoma. 1995 Oct;19(3-4):223-33 [8535213.001]
  • [Cites] Histol Histopathol. 2004 Jan;19(1):211-9 [14702189.001]
  • [Cites] Curr Opin Neurol. 2003 Dec;16(6):671-5 [14624075.001]
  • [Cites] Cancer. 2002 Jul 1;95(1):193-202 [12115333.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):261-6 [10659013.001]
  • [Cites] Pathol Res Pract. 1998;194(7):473-86 [9728364.001]
  • [Cites] J Neurovirol. 2002 Dec;8 Suppl 2:115-21 [12491162.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1504-10 [12237919.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1093-104 [8239229.001]
  • [Cites] Indian J Med Res. 2000 Jan;111:14-23 [10793489.001]
  • [Cites] Surg Neurol. 2002 Feb;57(2):113-6 [11904205.001]
  • [Cites] AIDS. 1998 Feb 12;12(3):309-13 [9517994.001]
  • [Cites] Neurol India. 2003 Jun;51(2):237-40 [14571012.001]
  • [Cites] Leuk Lymphoma. 2001 Mar;41(1-2):105-16 [11342362.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):378-84 [2155307.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(10):1298-312 [12091059.001]
  • [Cites] Acta Neuropathol Suppl. 1975;Suppl 6:95-102 [1098380.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;119(1):7-27 [1400570.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • (PMID = 15690139.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Bernstein WB, Little RF, Wilson WH, Yarchoan R: Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy. Int J Hematol; 2006 Jul;84(1):3-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired immunodeficiency syndrome-related malignancies in the era of highly active antiretroviral therapy.
  • Since the beginning of the acquired immunodeficiency syndrome (AIDS) epidemic, malignancies have been an important feature of this disease.
  • Several cancers, including Kaposi sarcoma (KS), certain aggressive B-cell lymphomas, and cervical cancer, are considered AIDS-defining when they occur in patients infected with human immunodeficiency virus.
  • Most AIDS-defining tumors are associated with one of 3 DNA viruses: KS-associated herpesvirus, Epstein-Barr virus, or human papillomavirus.
  • With the introduction of highly active antiretroviral therapy (HAART), the incidence of KS and certain lymphomas has decreased, whereas that of other tumors, such as cervical cancer, has undergone little change.
  • Several new drugs and therapies have been developed for KS and AIDS-related lymphomas, and these treatments, plus the development of HAART, have contributed to improvements in morbidity and mortality.
  • At the same time, the improved overall survival of patients with HAART has contributed to an increase in the number of patients living with AIDS in developed countries such as the United States.
  • With the development of HAART and improved prevention and treatment of opportunistic infections, an increasing percentage of the deaths in AIDS patients have been from malignancies.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related. Sarcoma, Kaposi
  • [MeSH-minor] AIDS-Related Opportunistic Infections / etiology. AIDS-Related Opportunistic Infections / mortality. AIDS-Related Opportunistic Infections / prevention & control. AIDS-Related Opportunistic Infections / virology. Humans

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Leuk Lymphoma. 1994 Feb;12(5-6):413-9 [8180604.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] Am J Pathol. 1998 Jun;152(6):1433-43 [9626048.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1369-77 [11070101.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] AIDS. 2002 Sep 6;16(13):1799-802 [12218392.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Curr Opin Oncol. 2000 Mar;12(2):174-80 [10750730.001]
  • [Cites] JAMA. 2000 Feb 23;283(8):1031-7 [10697063.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):405-8 [9670053.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2):143-53 [12704591.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):399-402 [14752065.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Mar;53(3):253-65 [15718150.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1072-85 [8214003.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Am J Med. 1991 Apr;90(4):427-33 [1707230.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] AIDS. 2004 Aug 20;18(12):1737-40 [15280789.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Jul 25;17(11):F17-22 [12853764.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Histopathology. 1994 Jul;25(1):77-82 [7959648.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1093-9 [10400426.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):24-5 [9422503.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2876-82 [12885804.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1181-5 [7700310.001]
  • [Cites] Radiother Oncol. 1998 Jan;46(1):19-22 [9488122.001]
  • [Cites] Int J STD AIDS. 1998 Dec;9(12):751-5 [9874123.001]
  • [Cites] Blood. 2004 Aug 1;104(3):810-4 [15073028.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1471-6 [15784870.001]
  • [Cites] Science. 1997 Oct 10;278(5336):290-4 [9323208.001]
  • [Cites] N Engl J Med. 1983 May 5;308(18):1071-6 [6835320.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1982 Jun 4;31(21):277-9 [6808345.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 19;87(8):581-6 [7538593.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Lancet. 1995 Jul 1;346(8966):26-8 [7603142.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2353-64 [8708728.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S42-8 [10430218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2173-6 [11264189.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • (PMID = 16867895.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Japan
  • [Number-of-references] 97
  •  go-up   go-down


49. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • A recent study of SAIDS-NHL demonstrated a lymphoma-derived cell line to be sensitive to the growth inhibitory effects of the ubiquitous cytokine, transforming growth factor-beta (TGF-beta).
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


50. Saloura V, Grivas PD, Mapow D, Kazmi K, Ward K, Styler M: Intracerebral progression of Hodgkin lymphoma in a man with HIV. Postgrad Med; 2009 Nov;121(6):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebral progression of Hodgkin lymphoma in a man with HIV.
  • Intracerebral relapse of Hodgkin lymphoma is a rare occurrence, with a reported incidence of < 0.5%.
  • We report the case of a human immunodeficiency virus (HIV)-seropositive man with disseminated Hodgkin lymphoma who presented with left facial weakness and sensory abnormalities as the only symptoms of disease progression 3 months after chemotherapy-induced disease remission.
  • Because of the relative rarity of the condition, there are no randomized controlled trials or evidence-based strategies for managing patients with HIV and intracerebral Hodgkin lymphoma.
  • The diagnostic difficulty of this case emphasizes the necessity for a high index of suspicion for the diagnosis of HIV-associated intracerebral lymphoma in the appropriate clinical setting.
  • In the post-genomic era, the development of sophisticated clinical and/or molecular biomarkers could contribute to earlier diagnosis and potentially improve disease prognosis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / virology. HIV Infections / complications. Hodgkin Disease / diagnosis. Hodgkin Disease / virology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Immunocompromised Host. Male. Middle Aged. Recurrence


51. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O: Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol; 2006;27(4):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
  • CD30, first described as the Ki antigen on malignant B cells in Hodgkin's lymphoma, is also expressed on normal activated B and T cells.
  • In a cross-sectional study utilizing archived sera at a time point close to but preceding a diagnosis of acquired immunodeficiency syndrome (AIDS)-associated non-Hodgkin's B cell lymphoma, AIDS lymphoma subjects (n = 49) showed elevated mean levels of sCD30 compared to controls with AIDS but no malignancy (n = 44, p < 0.01), HIV-infected but relatively healthy (n = 47, p < 0.001), or HIV-seronegative controls (n = 44, p < 0.001).
  • Serum sCD30 was significantly correlated to serum levels of the B cell cytokines interleukin-6 (IL-6), IL-10, and sCD23, but only among lymphoma subjects (p < or = 0.05).
  • Correlations between sCD30 and other markers of immune system activation were seen among all HIV-infected subjects (sCD27, sCD44, CXCL13, p < 0.05).
  • These observations suggest that sCD30, especially in combination with other immune system molecules, could be an important biomarker for an immune system environment conducive to B cell hyperactivation and the development of AIDS-associated B cell lymphoma.
  • [MeSH-major] Antigens, CD30 / blood. Lymphoma, AIDS-Related / immunology. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / physiopathology. Antigens, CD / blood. Biomarkers. CD4 Lymphocyte Count. HIV Infections / physiopathology. Humans. Interleukins / blood. Predictive Value of Tests. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16651853.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5-M01-RR-00722; United States / NIAID NIH HHS / AI / AI28697; United States / NCI NIH HHS / CA / CA73475; United States / NCI NIH HHS / CA / CA96888; United States / NIAID NIH HHS / AI / U01-AI-35043; United States / NIAID NIH HHS / AI / UO1-AI-35039; United States / NIAID NIH HHS / AI / UO1-AI-35040; United States / NIAID NIH HHS / AI / UO1-AI-35041; United States / NIAID NIH HHS / AI / UO1-AI-35042; United States / NIAID NIH HHS / AI / UO1-AI-37613; United States / NIAID NIH HHS / AI / UO1-AI-37984
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; 0 / Biomarkers; 0 / Interleukins
  •  go-up   go-down


52. Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL: Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn; 2010 Jan;12(1):58-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The somatic mutation JAK2 V617F is associated with BCR-ABL1-negative myeloproliferative neoplasms.
  • Detection of this mutation aids diagnosis of these neoplasms, and quantification of JAK2 V617F may provide a method to monitor response to therapy.
  • The assay characteristics and our initial evaluation indicate this method can be used for the detection and quantification of JAK2 V617F, which should be useful for diagnosis of myeloproliferative neoplasms and potentially for monitoring minimal residual disease in future trials of therapies targeted to myeloproliferative neoplasms.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Mar;20(3):471-6 [16408098.001]
  • [Cites] Trends Mol Med. 2005 Dec;11(12):546-54 [16271512.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1055-60 [16572198.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):330-4 [16825505.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1622 [16775613.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):397-411; quiz 526 [16931578.001]
  • [Cites] Leukemia. 2006 Nov;20(11):2067 [16990780.001]
  • [Cites] Exp Hematol. 2007 Jan;35(1):32-8 [17198871.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1316-21 [17018857.001]
  • [Cites] Leukemia. 2007 Apr;21(4):815-6; discussion 816-8 [17268517.001]
  • [Cites] J Mol Diagn. 2007 Apr;9(2):242-8 [17384217.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1658-68 [17541402.001]
  • [Cites] Br J Haematol. 2007 Oct;139(1):64-9 [17854308.001]
  • [Cites] Haematologica. 2008 Jan;93(1):41-8 [18166784.001]
  • [Cites] Annu Rev Med. 2008;59:213-22 [17919086.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):311-20 [18394554.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3931-40 [18160670.001]
  • [Cites] Blood. 2008 May 15;111(10):5109-17 [18334677.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1289 [18079740.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1299-307 [18496562.001]
  • [Cites] Leukemia. 2008 Sep;22(9):1790-2 [18354492.001]
  • [Cites] Haematologica. 2008 Nov;93(11):1723-7 [18728027.001]
  • [Cites] Int J Lab Hematol. 2010 Feb;32(1 Pt 2):95-102 [19254349.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1207-9 [15860661.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3387-95 [10779328.001]
  • [Cites] Blood. 1965 Nov;26(5):657-67 [5845783.001]
  • [Cites] Nucleic Acids Res. 1989 Apr 11;17(7):2503-16 [2785681.001]
  • [Cites] Am J Hematol. 1999 May;61(1):10-5 [10331505.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3377-9 [16081687.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):177-94 [16321848.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):651-3 [16707363.001]
  • (PMID = 19959796.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA049605; United States / NCI NIH HHS / CA / 2P01CA49605
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.2.1.12 / Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); EC 2.7.10.2 / Janus Kinase 2
  • [Other-IDs] NLM/ PMC2797719
  •  go-up   go-down


53. Bortolin MT, Simonelli C, Zanussi S, Pratesi C, Bidoli E, Rupolo M, Berretta M, Tedeschi R, De Paoli P: Effects on virological and immunological parameters during CD34 mobilization in HIV patients with lymphoma. Am J Hematol; 2006 Oct;81(10):800-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects on virological and immunological parameters during CD34 mobilization in HIV patients with lymphoma.
  • The effects of CD34 mobilization with chemotherapy and G-CSF administration were evaluated in 13 HIV-positive patients with relapsed lymphomas and low CD4 counts.
  • After mobilization, CD4+ cells increased significantly while HIV-RNA and integrated HIV-DNA showed no increases.
  • G-CSF led to an increase of CD4+ cells with limited effects on HIV replication.
  • [MeSH-major] Antigens, CD34 / immunology. HIV Infections / immunology. Hematopoietic Stem Cell Mobilization. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838324.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / RNA, Viral; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


54. Corti M, Villafañe MF, Trione N, Narbaitz M: [Hodgkin lymphoma associated with human immunodeficiency virus type-1 infection: epidemiologic, clinic and histopathologic findings in 18 patients]. Med Clin (Barc); 2005 Jan 29;124(3):116-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin lymphoma associated with human immunodeficiency virus type-1 infection: epidemiologic, clinic and histopathologic findings in 18 patients].
  • [Transliterated title] Linfoma de Hodgkin asociado con la infección por VIH-1: análisis epidemiológico, clínico, virológico e histopatológico de 18 pacientes.
  • [MeSH-major] HIV Infections. HIV-1. Hodgkin Disease. Lymphoma, AIDS-Related


55. Johnson RW, Wasner G, Saddier P, Baron R: Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging; 2008;25(12):991-1006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HZ incidence is higher in persons who are immunocompromised as a result of disease (e.g. malignancies such as lymphoma, HIV/AIDS, diabetes mellitus) or treatments such as chemotherapy and radiotherapy.


56. Ozaras R, Ar C, Ongoren S, Mete B, Tabak F, Mert A, Ozturk R: Acute hepatitis B despite a previous high titer of anti-HBs. Hepatol Int; 2010;4(2):530-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute hepatitis B despite a previous high titer of anti-HBs.
  • INTRODUCTION: Loss of HBsAg and development of surface and core antibodies represent clinical cure.
  • However, recent evidence suggests that hepatitis B virus (HBV) persists in a latent state even in those with mounted protective antibodies.
  • After significant immunosuppression, anti-HBs may decrease and HBsAg may reappear (reverse seroconversion).
  • Reverse seroconversion of HBV has been observed in association with hematopoietic stem cell transplantation, renal transplantation, intensive chemotherapy, human immunodeficiency infection, or rituximab usage.
  • CASE REPORT: We present here a case study of a patient with a previous high titer of anti-HBs who later developed HBV reactivation following intensive chemotherapy for leukemia.
  • CONCLUSION: We conclude that in immunosuppressed patients with a history of HBV infection may carry a risk for reverse seroconversion and monitoring anti-HBs levels may help recognising this risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20827412.001).
  • [ISSN] 1936-0541
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2900550
  • [Keywords] NOTNLM ; Hepatitis B virus / Immunosuppression / Reverse seroconversion
  •  go-up   go-down


57. Mounier N, Spina M, Gisselbrecht C: Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol; 2007 Mar;136(5):685-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern management of non-Hodgkin lymphoma in HIV-infected patients.
  • Patients infected with human immunodeficiency virus (HIV) are at greater risk of developing non-Hodgkin lymphoma than the general population and aggressive B-cell lymphoma has become one of the most common of the initial acquired immunodeficiency syndrome (AIDS)-defining illnesses.
  • This review considers the prognostic factors and new approaches to the treatment of patients with AIDS-related lymphoma (ARL).
  • As highly active antiretroviral therapy (HAART) became available, the survival of many ARL patients has become comparable to that of HIV-negative patients.
  • Both developments can also be attributed to new treatment strategies for ARL, such as the use of effective infusional regimens, Rituximab combinations and high-dose therapy with autologous stem-cell transplantation for relapsed disease.
  • [MeSH-major] Lymphoma, AIDS-Related / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / drug therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Hematopoietic Stem Cell Transplantation. Humans. Prognosis. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229246.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 83
  •  go-up   go-down


58. Dewan MZ, Tomita M, Katano H, Yamamoto N, Ahmed S, Yamamoto M, Sata T, Mori N, Yamamoto N: An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer; 2009 Feb 1;124(3):622-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells.
  • Epstein-Barr Virus (EBV)-associated immunoblastic lymphoma occurs in immunocompromised patients such as those with AIDS or transplant recipients after primary EBV infection or reactivation of a preexisting latent EBV infection.
  • In the present study, we evaluated the effect of ritonavir, an HIV protease inhibitor, on EBV-positive lymphoblastoid B cells in vitro and in mice model.
  • Ritonavir efficiently prevented growth and infiltration of lymphoma cells in various organs of NOD/SCID/gammacnull mice at the same dose used for treatment of patients with AIDS.
  • These data also suggest that this compound may have promise for treatment or prevention of EBV-associated lymphoproliferative diseases that occur in immunocompromised patients.
  • [MeSH-major] Epstein-Barr Virus Infections / drug therapy. HIV Protease Inhibitors / pharmacology. Lymphoma, B-Cell / drug therapy. NF-kappa B / drug effects. Ritonavir / pharmacology

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973272.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Protease Inhibitors; 0 / NF-kappa B; O3J8G9O825 / Ritonavir
  •  go-up   go-down


59. Subsai K, Kanoksri S, Siwaporn C, Helen L, Kanokporn O, Wantana P: Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study. Eur J Neurol; 2006 Mar;13(3):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurological complications in AIDS patients receiving HAART: a 2-year retrospective study.
  • The positive role of highly active anti-retroviral therapy (HAART) in reducing opportunistic infections in acquired immunodeficiency syndrome (AIDS) patients is well known.
  • In northern Thailand, GPO-vir (Stavudine-D4T + Lamivudine-3TC + Nevirapine-NVP) has been promoted for the treatment of AIDS patients since April 2002, in accordance with the Government Pharmaceutical Organization's guidelines.
  • However, the incidence rates of IRIS affecting nervous system (NIRIS) and non-NIRIS in comparison with the previous incidence of AIDS-defining disease have not been reported.
  • We conducted a retrospective study to review the incidence of NIRIS and non-NIRIS in AIDS patients treated with GPO-vir in Chiang Mai University Hospital, Thailand, between May 2002 and April 2004.
  • Altogether 506 AIDS patients were treated with GPO-vir during the specified period.
  • The overall incidence of NIRIS, including progressive multifocal leukoencephalopathy (PML), cerebral toxoplasmosis and cytomegalovirus (CMV) retinitis, was lower than the previous incidence of AIDS-defining disease in the pre-HAART era.
  • However, the incidence of ischemic stroke, hemorrhagic stroke and primary central nervous system (CNS) lymphoma had increased.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anti-HIV Agents / adverse effects. Antiretroviral Therapy, Highly Active / methods. Nervous System Diseases / etiology


60. Tanaka PY, Pracchia LF, Calore EE: Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil. Int J Hematol; 2006 Nov;84(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
  • The relative risk of non-Hodgkin's lymphoma (NHL) among patients infected with human immunodeficiency virus (HIV) is elevated compared with the general population.
  • We describe a retrospective study of 78 HIV-infected patients with NHL treated between 1999 and 2006 at the Infectology Institute, a reference center for HIV treatment in São Paulo, Brazil.
  • A univariate analysis showed a significant CR rate in patients with respect to the following factors: no acquired immunodeficiency syndrome (AIDS) diagnosis prior to the lymphoma, disease stage of I to II, and an International Prognostic Index (IPI) of low or low-intermediate risk.
  • A multivariate analysis indicated that only a previous AIDS diagnosis and the IPI were significantly related to the CR rate.
  • A median disease-free survival (DFS) time for the patients who achieved a CR was not reached, with a mean survival time of 73 months and a 3-year DFS rate of 77.5%.
  • Our results provide additional information regarding HIV-related lymphoma in Brazil.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Brazil. Cyclophosphamide. Disease-Free Survival. Doxorubicin. Female. Humans. Male. Middle Aged. Prednisolone. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1165-73 [8118021.001]
  • [Cites] N Engl J Med. 1997 Jun 5;336(23):1641-8 [9171066.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2006 Apr 1;107(7):3014-5 [16554492.001]
  • [Cites] Blood. 1992 Jul 1;80(1):8-20 [1319239.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):79-87 [10561022.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2171-8 [11304769.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1521-9 [12824790.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Lancet. 2000 Jul 22;356(9226):291-6 [11071184.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):442-53 [10950371.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Ann Intern Med. 1985 Sep;103(3):402-3 [2992336.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1927-32 [9731049.001]
  • [Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]
  • (PMID = 17118760.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


61. Uçkay I, Garbino J, Dietrich PY, Ninet B, Rohner P, Jacomo V: Recurrent bacteremia with Helicobacter cinaedi: case report and review of the literature. BMC Infect Dis; 2006;6:86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of a patient with lymphoma hospitalized for chemotherapy.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Apr;128(4):1023-33 [15825083.001]
  • [Cites] Infection. 2004 Dec;32(6):367-8 [15597229.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2261-6 [10834986.001]
  • [Cites] Clin Infect Dis. 2000 Jul;31(1):201-2 [10913427.001]
  • [Cites] Acta Gastroenterol Belg. 2000 Oct-Dec;63(4):380-7 [11233522.001]
  • [Cites] J Antimicrob Chemother. 2001 Apr;47(4):459-61 [11266421.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1580-5 [11283091.001]
  • [Cites] J Antimicrob Chemother. 2001 Aug;48(2):295-7 [11481305.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1511-3 [11923384.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):1908-12 [12037042.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3732-6 [12904383.001]
  • [Cites] J Infect Dis. 2003 Dec 15;188(12):1892-7 [14673770.001]
  • [Cites] J Infect Chemother. 2003 Dec;9(4):344-7 [14691657.001]
  • [Cites] J Infect Dis. 1985 Jan;151(1):131-9 [3965584.001]
  • [Cites] J Clin Microbiol. 1987 May;25(5):942-3 [3584432.001]
  • [Cites] Med J Aust. 1989 Feb 20;150(4):214-5 [2716603.001]
  • [Cites] Rev Infect Dis. 1991 Nov-Dec;13(6):1066-8 [1775838.001]
  • [Cites] J Infect. 1993 Jan;26(1):97-101 [8454896.001]
  • [Cites] J Clin Microbiol. 1993 Mar;31(3):569-71 [8458951.001]
  • [Cites] Epidemiol Infect. 1993 Jun;110(3):567-73 [8519321.001]
  • [Cites] Ann Intern Med. 1994 Jul 15;121(2):90-3 [8017741.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):564-70 [7756476.001]
  • [Cites] Clin Infect Dis. 1995 Oct;21(4):1055 [8645814.001]
  • [Cites] Clin Infect Dis. 1996 Apr;22(4):710-11 [8729212.001]
  • [Cites] Scand J Infect Dis. 1996;28(2):199-203 [8792493.001]
  • [Cites] Int J STD AIDS. 1997 Jan;8(1):59-60 [9043985.001]
  • [Cites] Semin Gastrointest Dis. 1997 Jul;8(3):124-41 [9232726.001]
  • [Cites] J Formos Med Assoc. 1997 Jul;96(7):558-60 [9262063.001]
  • [Cites] Comp Immunol Microbiol Infect Dis. 1999 Jan;22(1):41-61 [10099028.001]
  • [Cites] Scand J Infect Dis. 2005;37(5):382-5 [16051580.001]
  • (PMID = 16719920.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 30
  • [Other-IDs] NLM/ PMC1482711
  •  go-up   go-down


62. Johanson CE, Duncan JA, Stopa EG, Baird A: Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res; 2005 Jul;22(7):1011-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, drugs directed to CSF can modulate a variety of endocrine, immunologic, and behavioral phenomema; and can help to restore brain interstitial and cellular homeostasis disrupted by disease and trauma.
  • It also recapitulates how pharmacologic agents administered into the CSF system prevent disease or enhance the brain's ability to recover from chemical and physical insults.
  • The progressively increasing pharmacological significance of the CP-CSF nexus is analyzed in light of treating AIDS, multiple sclerosis, stroke, hydrocephalus, and Alzheimer's disease.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroscience. 1999;93(2):537-49 [10465437.001]
  • [Cites] Exp Neurol. 2001 Jan;167(1):40-7 [11161591.001]
  • [Cites] Brain Res. 2005 Jan 25;1032(1-2):183-92 [15680958.001]
  • [Cites] J Neurovirol. 2000 Dec;6(6):498-506 [11175322.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):921-8 [10544031.001]
  • [Cites] J Toxicol Environ Health A. 2003 Mar 14;66(5):435-51 [12712631.001]
  • [Cites] Adv Neurol. 1990;52:431-9 [2396537.001]
  • [Cites] Neurol Res. 2001 Jun;23(4):353-8 [11428515.001]
  • [Cites] J Neurosci Methods. 2005 Mar 15;142(1):115-24 [15652624.001]
  • [Cites] Arch Ophthalmol. 2002 Nov;120(11):1540-3 [12427069.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2919-31 [7773943.001]
  • [Cites] FASEB J. 2001 Jan;15(1):155-163 [11149903.001]
  • [Cites] Tissue Cell. 1978;10(2):331-42 [675669.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11297-302 [11027330.001]
  • [Cites] Curr Opin Biotechnol. 1996 Dec;7(6):616-21 [8939640.001]
  • [Cites] Brain. 2002 Aug;125(Pt 8):1859-74 [12135976.001]
  • [Cites] Brain. 2003 Mar;126(Pt 3):623-31 [12566283.001]
  • [Cites] Ann N Y Acad Sci. 1988;531:29-39 [3382143.001]
  • [Cites] Trends Immunol. 2001 Sep;22(9):483-90 [11525938.001]
  • [Cites] Neurol Res. 2003 Sep;25(6):625-34 [14503017.001]
  • [Cites] Curr Pharm Biotechnol. 2002 Mar;3(1):45-57 [11883506.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2076-80 [8134351.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1062-9 [12183664.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):112-29 [11135454.001]
  • [Cites] Neurology. 2001 Nov 27;57(10):1763-6 [11723260.001]
  • [Cites] Glia. 1998 Mar;22(3):260-71 [9482212.001]
  • [Cites] Exp Brain Res. 1974 Apr 30;20(1):18-31 [4276939.001]
  • [Cites] Neuroreport. 1995 May 9;6(7):1005-9 [7543300.001]
  • [Cites] Neuroscience. 2000;101(4):957-67 [11113345.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 22;876:119-30 [10415600.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):83-8 [11135451.001]
  • [Cites] J Neurochem. 2005 Apr;93(1):26-37 [15773902.001]
  • [Cites] Neurol Res. 2004 Mar;26(2):226-9 [15072643.001]
  • [Cites] J Neurochem. 2003 Feb;84(4):725-34 [12562517.001]
  • [Cites] Lab Invest. 1987 Mar;56(3):231-3 [2950275.001]
  • [Cites] Am J Physiol. 1999 Mar;276(3 Pt 2):R818-23 [10070143.001]
  • [Cites] Cell Mol Neurobiol. 2000 Apr;20(2):231-53 [10696512.001]
  • [Cites] Neurosci Lett. 2004 Jul 8;364(3):145-8 [15196664.001]
  • [Cites] J Comp Neurol. 1998 Oct 19;400(2):175-96 [9766398.001]
  • [Cites] Exp Neurol. 1999 Nov;160(1):109-16 [10630195.001]
  • [Cites] Cell Tissue Res. 2004 Mar;315(3):361-73 [14722750.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Feb;80(2):289-96 [15680182.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Nov;281(5):H1881-9 [11668047.001]
  • [Cites] Brain Res. 1980 May 19;190(1):3-16 [6769537.001]
  • [Cites] Neuron. 2004 Aug 5;43(3):333-44 [15294142.001]
  • [Cites] J Comp Neurol. 2000 Dec 4;428(1):62-78 [11058225.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94 [12829791.001]
  • [Cites] Curr Pharm Des. 2004;10(12):1365-70 [15134487.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2004 Jul;287(1):H331-9 [14962837.001]
  • [Cites] Acta Neuropathol. 1992;83(3):233-9 [1373020.001]
  • [Cites] Glia. 2003 Dec;44(3):190-204 [14603461.001]
  • [Cites] Cancer Gene Ther. 2001 Jan;8(1):3-8 [11219491.001]
  • [Cites] Hypertension. 2002 May;39(5):1028-34 [12019287.001]
  • [Cites] Tokai J Exp Clin Med. 2004 Dec;29(4):167-73 [15717488.001]
  • [Cites] J Neurovirol. 2002 Jun;8(3):225-39 [12053277.001]
  • [Cites] J Virol. 2001 May;75(10):4681-91 [11312339.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):215-20 [15072470.001]
  • [Cites] J Neurochem. 1994 Mar;62(3):1089-96 [8113796.001]
  • [Cites] Eur J Neurosci. 2002 Sep;16(6):1045-57 [12383233.001]
  • [Cites] Neurosci Behav Physiol. 2004 Nov;34(9):929-33 [15686138.001]
  • [Cites] J Neurosci. 2005 Feb 23;25(8):1904-13 [15728830.001]
  • [Cites] J Neurovirol. 2000 May;6 Suppl 1:S70-81 [10871768.001]
  • [Cites] J Neurochem. 1981 Jul;37(1):117-24 [7252498.001]
  • [Cites] Pharm Res. 2000 Jan;17(1):63-9 [10714610.001]
  • [Cites] Exp Brain Res. 1996 Mar;108(3):427-32 [8801122.001]
  • [Cites] J Neurochem. 1989 Apr;52(4):1058-63 [2926388.001]
  • [Cites] Cell Tissue Res. 2004 Aug;317(2):147-64 [15221441.001]
  • [Cites] J Comp Neurol. 2001 Jun 11;434(4):461-77 [11343293.001]
  • [Cites] Cancer. 1975 Mar;35(3 suppl):965-72 [1111955.001]
  • [Cites] Brain Res Dev Brain Res. 1990 Oct 1;56(1):47-53 [2279331.001]
  • [Cites] J Neurosci Res. 2004 Apr 15;76(2):205-15 [15048918.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Mar;24(3):271-9 [15091107.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Oct 14;56(12):1811-24 [15381335.001]
  • [Cites] Exp Neurol. 2003 Dec;184(2):904-11 [14769382.001]
  • [Cites] Brain Res. 1998 May 18;793(1-2):219-30 [9630636.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):323-7 [9920102.001]
  • [Cites] Cell Tissue Res. 2001 Aug;305(2):267-73 [11545264.001]
  • [Cites] IEEE Trans Biomed Eng. 2001 May;48(5):560-9 [11341530.001]
  • [Cites] J Neuroimmunol. 1993 Jul;46(1-2):25-31 [8360331.001]
  • [Cites] Neuroreport. 2002 Feb 11;13(2):257-9 [11893921.001]
  • [Cites] Curr Drug Metab. 2004 Feb;5(1):95-108 [14965253.001]
  • [Cites] J Physiol. 1978 Feb;275:167-76 [633102.001]
  • [Cites] Circulation. 2004 Jan 27;109(3):424-31 [14707023.001]
  • [Cites] Histol Histopathol. 2002 Jan;17 (1):273-88 [11813877.001]
  • [Cites] Sci Am. 1989 Nov;261(5):68-74 [2479097.001]
  • [Cites] Acta Neuropathol. 1997 May;93(5):494-500 [9144588.001]
  • [Cites] Brain Res. 1996 Jul 8;726(1-2):174-80 [8836558.001]
  • [Cites] Brain Res. 1992 Aug 7;587(2):216-25 [1525658.001]
  • [Cites] Stroke. 2003 Jun;34(6):1519-25 [12730553.001]
  • [Cites] Kidney Int. 2004 Feb;65(2):409-19 [14717911.001]
  • [Cites] Gene Ther. 2003 Jan;10(1):34-42 [12525835.001]
  • [Cites] Neurosci Lett. 1994 Mar 14;169(1-2):159-62 [8047274.001]
  • [Cites] Br J Pharmacol. 1998 Sep;125(1):49-54 [9776343.001]
  • [Cites] Cancer Gene Ther. 1995 Jun;2(2):87-95 [7621261.001]
  • [Cites] Stroke. 1982 Jul-Aug;13(4):499-504 [7101351.001]
  • [Cites] Science. 1992 Mar 27;255(5052):1707-10 [1553558.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1693-9 [12457283.001]
  • [Cites] Am J Physiol. 1994 May;266(5 Pt 2):R1488-92 [8203625.001]
  • [Cites] Neuroreport. 2004 Jul 19;15(10):1543-7 [15232280.001]
  • [Cites] J Neurovirol. 2002 Jun;8(3):211-24 [12053276.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):53-67 [7604885.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):977-8 [15458607.001]
  • [Cites] Cerebrospinal Fluid Res. 2004 Dec 10;1(1):3 [15679944.001]
  • [Cites] Rinsho Shinkeigaku. 2000 Dec;40(12):1297-9 [11464484.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Sep;21(9):1125-31 [11524617.001]
  • [Cites] Endocrinology. 2004 Apr;145(4):2006-13 [14715716.001]
  • [Cites] Endocrinology. 2000 Apr;141(4):1434-41 [10746647.001]
  • [Cites] Am J Physiol. 1981 Apr;240(4):F319-28 [7223889.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Mol Genet Metab. 2003 Aug;79(4):233-44 [12948739.001]
  • [Cites] Brain Res. 2002 Sep 27;951(1):135-40 [12231467.001]
  • [Cites] J Neurochem. 1996 Sep;67(3):964-71 [8752101.001]
  • [Cites] Brain Res. 1995 Sep 11;691(1-2):1-8 [8590041.001]
  • [Cites] Neuroscience. 2003;122(4):853-67 [14643756.001]
  • [Cites] Mol Cell Neurosci. 2004 Nov;27(3):280-95 [15519243.001]
  • [Cites] Eur J Pediatr Surg. 2001 Dec;11 Suppl 1:S37-8 [11848043.001]
  • [Cites] J Neurosurg. 1978 Jun;48(6):883-94 [96228.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Oct;20(10):1072-86 [15585098.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Oct 14;56(12):1825-57 [15381336.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1094-102 [12066912.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1473-85 [12824785.001]
  • [Cites] Gene Ther. 2003 Aug;10(17):1528-34 [12900769.001]
  • [Cites] J Physiol. 1980 Feb;299:353-65 [6155466.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Mar;21(3):233-43 [11295878.001]
  • [Cites] Pediatr Neurol. 2002 Apr;26(4):305-8 [11992760.001]
  • [Cites] Brain Res. 2003 Oct 24;988(1-2):105-13 [14519531.001]
  • [Cites] Hum Gene Ther. 1996 May 1;7(7):841-50 [8860836.001]
  • [Cites] Pharmacology. 2000 Feb;60(2):58-73 [10657755.001]
  • [Cites] Cell Mol Neurobiol. 2000 Apr;20(2):197-216 [10696510.001]
  • [Cites] Endocrinology. 1994 Nov;135(5):2255-64 [7525264.001]
  • [Cites] Am J Physiol. 1990 Jun;258(6 Pt 2):F1528-37 [2163213.001]
  • [Cites] J Exp Med. 1998 Aug 17;188(4):635-49 [9705946.001]
  • [Cites] Neurosci Behav Physiol. 2004 Sep;34(7):659-62 [15526418.001]
  • [Cites] J Neurosci. 1996 Apr 15;16(8):2649-58 [8786441.001]
  • [Cites] Pediatr Res. 1999 Nov;46(5):576-80 [10541321.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 May;24(5):548-55 [15129187.001]
  • [Cites] Endocrinology. 2003 Jan;144(1):281-91 [12488356.001]
  • [Cites] Neurosci Lett. 1993 Feb 19;150(2):174-8 [8097029.001]
  • [Cites] Brain Res. 2004 Oct 22;1024(1-2):150-8 [15451377.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Feb;280(2):E349-56 [11158940.001]
  • [Cites] J Neurosci. 2001 Sep 1;21(17):6718-31 [11517261.001]
  • [Cites] Pain. 2005 Mar;114(1-2):195-202 [15733645.001]
  • [Cites] Brain Res Dev Brain Res. 1996 May 31;93(1-2):182-90 [8804705.001]
  • [Cites] Regul Pept. 1998 Sep 25;75-76:425-31 [9802439.001]
  • [Cites] Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):158-61 [13129802.001]
  • [Cites] Gene Ther. 2001 Aug;8(15):1167-73 [11509947.001]
  • [Cites] Arch Neurol. 1995 Sep;52(9):912-7 [7661730.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;977:454-67 [12480786.001]
  • [Cites] J Neurocytol. 2000 Oct;29(10):707-17 [11387545.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33382-7 [10559217.001]
  • [Cites] J Neurochem. 2002 Feb;80(3):392-404 [11905988.001]
  • [Cites] Neuropsychopharmacology. 2004 Mar;29(3):450-60 [14872203.001]
  • [Cites] Methods Enzymol. 2000;328:333-63 [11075354.001]
  • [Cites] Brain Res Brain Res Rev. 1992 May-Aug;17(2):109-38 [1393190.001]
  • [Cites] Brain Res Dev Brain Res. 1990 Sep 1;55(2):203-8 [1701364.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Mar;308(3):912-20 [14634041.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Sep;306(3):1035-41 [12766261.001]
  • [Cites] J Neurochem. 2003 Oct;87(1):76-84 [12969254.001]
  • [Cites] Am J Physiol. 1994 Feb;266(2 Pt 2):H393-8 [8141339.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Aug;16(4):293-303 [2234311.001]
  • [Cites] J Neurosci Res. 2005 Mar 1;79(5):714-23 [15678515.001]
  • [Cites] Exp Neurol. 1981 Jun;72(3):645-53 [6786911.001]
  • [Cites] Br J Pharmacol. 2000 May;130(2):242-8 [10807660.001]
  • [Cites] Brain Res. 2000 Jun 16;868(1):48-55 [10841887.001]
  • [Cites] Neurosci Lett. 1996 May 10;209(2):117-20 [8761996.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):50-8 [12941460.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):85-7 [2380099.001]
  • [Cites] Eur J Pediatr Surg. 2000 Dec;10 Suppl 1:44-6 [11214837.001]
  • [Cites] J Neurosci. 2000 Feb 15;20(4):1318-23 [10662821.001]
  • [Cites] Am J Physiol. 1999 Jan;276(1 Pt 1):C82-90 [9886923.001]
  • [Cites] Acta Neuropathol. 2002 Sep;104(3):217-24 [12172906.001]
  • [Cites] Exp Neurol. 1997 Jun;145(2 Pt 1):329-41 [9217070.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):885-94 [9786239.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Microsc Res Tech. 2001 Mar 1;52(5):573-90 [11241867.001]
  • [Cites] Trends Neurosci. 2000 May;23(5):209-16 [10782126.001]
  • [Cites] Am J Clin Nutr. 1992 Jan;55(1 Suppl):278S-282S [1370249.001]
  • [Cites] Am J Physiol. 1995 Jul;269(1 Pt 2):R73-9 [7631906.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 2):R263-71 [10409281.001]
  • [Cites] Neuroscience. 2000;95(2):577-92 [10658638.001]
  • [Cites] Brain Res. 1997 Mar 21;751(2):181-8 [9099804.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jul;59(7):561-74 [10901227.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7567-72 [10840060.001]
  • [Cites] Brain Pathol. 2002 Jul;12(3):308-19 [12146799.001]
  • [Cites] Stroke. 2004 Sep;35(9):2206-10 [15284450.001]
  • [Cites] Regul Pept. 2000 Aug 25;92(1-3):57-64 [11024566.001]
  • [Cites] J Neurooncol. 1997 Sep;34(2):139-44 [9210060.001]
  • [Cites] J Neuroimmunol. 2001 Apr 2;115(1-2):135-43 [11282163.001]
  • [Cites] Am J Physiol. 1986 Sep;251(3 Pt 2):F485-9 [3752258.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17(1):13-9 [12615045.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):422-5 [12140559.001]
  • [Cites] J Pharmacol Exp Ther. 1975 Oct;195(1):73-83 [810575.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Mar;106(2):82-7 [15003295.001]
  • [Cites] Am J Physiol. 1982 Sep;243(3):R400-7 [7114296.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] J Neurovirol. 2004;10 Suppl 1:21-4 [14982735.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2002 Mar;48(2):205-12 [11990457.001]
  • [Cites] Neurotox Res. 1999 Dec;1(2):81-90 [12835104.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13131-6 [12232046.001]
  • [Cites] Exp Neurol. 2001 Feb;167(2):242-51 [11161612.001]
  • [Cites] Acta Neurochir Suppl. 1997;70:285-7 [9416348.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Feb 29;355(1394):275-80 [10724461.001]
  • [Cites] Anim Reprod Sci. 2005 Apr;86(3-4):221-35 [15766802.001]
  • [Cites] J Comp Neurol. 2001 Apr 23;433(1):101-14 [11283952.001]
  • [Cites] Hum Gene Ther. 1998 Nov 1;9(16):2393-9 [9829538.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 2003;113-114:57-65 [15686107.001]
  • [Cites] Neurochem Res. 2005 Jan;30(1):69-73 [15756934.001]
  • [Cites] Trends Neurosci. 2004 Oct;27(10):589-94 [15374669.001]
  • [Cites] Neurosci Lett. 2005 Mar 3;375(3):143-7 [15694248.001]
  • [Cites] Can J Physiol Pharmacol. 2003 Apr;81(4):317-28 [12769224.001]
  • [Cites] Lancet Neurol. 2003 Aug;2(8):506-11 [12878439.001]
  • [Cites] Neurochem Int. 2004 Sep;45(4):545-52 [15186921.001]
  • [Cites] J Neural Transm Gen Sect. 1992;87(1):49-62 [1531593.001]
  • [Cites] Eur J Clin Pharmacol. 1998 Jul;54(5):415-20 [9754986.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):768-77 [11487051.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Aug;20(7):1359-64 [10472998.001]
  • [Cites] Stroke. 1984 May-Jun;15(3):481-6 [6145238.001]
  • [Cites] Brain Res. 2005 Feb 21;1035 (1):67-72 [15713278.001]
  • [Cites] Toxicol Lett. 1995 Dec;82-83:645-53 [8597122.001]
  • [Cites] FASEB J. 2004 Jan;18(1):212-4 [14630698.001]
  • [Cites] Anesth Analg. 1997 Jan;84(1):139-47 [8989015.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11981-6 [9751776.001]
  • [Cites] J Sleep Res. 1999 Jun;8 Suppl 1:60-4 [10389108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82 [2201029.001]
  • [Cites] J Comp Neurol. 1997 Nov 17;388(2):265-92 [9368841.001]
  • [Cites] J Neurovirol. 2004;10 Suppl 1:38-43 [14982738.001]
  • [Cites] Exp Brain Res. 2005 Mar;161(4):502-11 [15747160.001]
  • [Cites] Hum Gene Ther. 1999 Sep 20;10(14):2347-54 [10515454.001]
  • [Cites] Anesthesiology. 2005 Mar;102(3):616-23 [15731601.001]
  • [Cites] Trends Neurosci. 2001 Dec;24(12):719-25 [11718877.001]
  • [Cites] Endocrinology. 1992 Aug;131(2):698-702 [1639017.001]
  • [Cites] Acta Paediatr Suppl. 2004 Feb;93(444):11-4 [15035455.001]
  • [Cites] Brain Res. 1985 Feb 4;326(1):47-63 [3971148.001]
  • [Cites] Mol Ther. 2001 Apr;3(4):476-84 [11319907.001]
  • [Cites] Neuroscience. 2004;127(1):43-52 [15219667.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Oct 14;56(12):1765-91 [15381333.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Jul;294(1):73-9 [10871297.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):213-6 [12241117.001]
  • [Cites] Brain Res. 2004 Oct 8;1023(1):121-5 [15364026.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2001 Feb;37(2):111-20 [11332736.001]
  • [Cites] Acta Neuropathol. 2001 Jan;101(1):22-6 [11194937.001]
  • [Cites] Neurobiol Aging. 2004 May-Jun;25(5):589-97; discussion 603-4 [15172734.001]
  • [Cites] Arch Biochem Biophys. 1997 Mar 1;339(1):79-84 [9056236.001]
  • [Cites] J Neuroimmunol. 1994 Jan;49(1-2):125-34 [8294551.001]
  • [Cites] Brain Res. 1986 May 21;374(1):137-46 [3719323.001]
  • [Cites] J Neurosurg. 1997 Nov;87(5):694-9 [9347977.001]
  • [Cites] Exp Neurol. 2004 Jun;187(2):266-78 [15144853.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Aug;40(1):1-14 [8840007.001]
  • [Cites] Expert Opin Biol Ther. 2004 Aug;4(8):1191-201 [15268655.001]
  • [Cites] J Cereb Blood Flow Metab. 1985 Sep;5(3):401-12 [3928638.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1999 Jan;26(1):11-9 [10027064.001]
  • (PMID = 16028003.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS-27601
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 267
  •  go-up   go-down


63. Grayson W: The HIV-positive skin biopsy. J Clin Pathol; 2008 Jul;61(7):802-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HIV-positive skin biopsy.
  • Dermatological disorders are a frequent presenting feature of HIV infection and/or AIDS.
  • More than 90% of HIV-infected patients will suffer from one or more skin diseases during the course of their illness.
  • This trend is reflected in the increasing number of skin biopsies from HIV-positive patients in those parts of the world where HIV infection/AIDS is highly prevalent.
  • Histopathologists are therefore required to possess a working knowledge of the broad spectrum of cutaneous manifestations of HIV infection.
  • These include the range of dermatoses that are specific to HIV infection, the more common dermatoses occurring with greater frequency (or modified by) HIV infection/AIDS, the spectrum of infectious diseases (often opportunistic) caused by viruses, bacteria, fungi, protozoa and even arthropods, and neoplastic conditions such as Kaposi sarcoma and B-cell non-Hodgkin lymphoma.
  • [MeSH-major] HIV Infections / complications. Skin Diseases / pathology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / pathology. Anti-HIV Agents / adverse effects. Biopsy. Drug Eruptions / etiology. Drug Eruptions / pathology. Humans. Skin Diseases, Viral / complications. Skin Diseases, Viral / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006666.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Number-of-references] 142
  •  go-up   go-down


64. Chargari C, Zefkili S, Kirova YM: Potential of helical tomotherapy for sparing critical organs in a patient with AIDS who was treated for Hodgkin lymphoma. Clin Infect Dis; 2009 Mar 1;48(5):687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of helical tomotherapy for sparing critical organs in a patient with AIDS who was treated for Hodgkin lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Hodgkin Disease / radiotherapy. Radiotherapy / methods


65. Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT: Clinical significance of enteric protozoa in the immunosuppressed human population. Clin Microbiol Rev; 2009 Oct;22(4):634-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Globally, the number of immunosuppressed people increases each year, with the human immunodeficiency virus (HIV) pandemic continuing to spread unabated in many parts of the world.
  • Components of the immune system can be functionally or genetically abnormal as a result of acquired (e.g., caused by HIV infection, lymphoma, or high-dose steroids or other immunosuppressive medications) or congenital illnesses, with more than 120 congenital immunodeficiencies described to date that either affect humoral immunity or compromise T-cell function.
  • All individuals affected by immunosuppression are at risk of infection by opportunistic parasites (such as the microsporidia) as well as those more commonly associated with gastrointestinal disease (such as Giardia).
  • The outcome of infection by enteric protozoan parasites is dependent on absolute CD4(+) cell counts, with lower counts being associated with more severe disease, more atypical disease, and a greater risk of disseminated disease.
  • This review summarizes our current state of knowledge on the significance of enteric parasitic protozoa as a cause of disease in immunosuppressed persons and also provides guidance on recent advances in diagnosis and therapy for the control of these important parasites.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / immunology. AIDS-Related Opportunistic Infections / parasitology. AIDS-Related Opportunistic Infections / pathology. Antiprotozoal Agents / therapeutic use. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Microbiol. 2006 Aug;9(4):367-73 [16824782.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2006 Aug;3(8):436-45 [16883348.001]
  • [Cites] Vet Parasitol. 2006 Sep 10;140(3-4):204-16 [16647210.001]
  • [Cites] J Egypt Soc Parasitol. 2006 Aug;36(2):613-27 [16927872.001]
  • [Cites] Nat Clin Pract Nephrol. 2006 Sep;2(9):490-503 [16941042.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):458-64 [18030213.001]
  • [Cites] Future Microbiol. 2007 Dec;2(6):583-90 [18041899.001]
  • [Cites] Bull World Health Organ. 2008 Sep;86(9):710-7 [18797647.001]
  • [Cites] J Zoo Wildl Med. 2008 Sep;39(3):493-5 [18817019.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Nov;5(11):637-47 [18813221.001]
  • [Cites] Trans R Soc Trop Med Hyg. 2008 Dec;102(12):1274-8 [18602128.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jun;50(6):2146-55 [16723577.001]
  • [Cites] Int J Infect Dis. 1999 Summer;3(4):203-6 [10575149.001]
  • [Cites] AIDS. 1999 Dec 3;13(17):2421-8 [10597784.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):167-8 [10602740.001]
  • [Cites] J Clin Microbiol. 1998 Apr;36(4):995-8 [9542924.001]
  • [Cites] Am J Trop Med Hyg. 1998 Apr;58(4):431-5 [9574787.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1373-7 [9593027.001]
  • [Cites] J Infect Dis. 1998 May;177(5):1443-6 [9593044.001]
  • [Cites] Arch Intern Med. 1998 May 25;158(10):1121-5 [9605784.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):911-4 [9634430.001]
  • [Cites] Folia Parasitol (Praha). 1998;45(2):140-8 [9684324.001]
  • [Cites] J Infect. 1998 Jul;37(1):48-53 [9733379.001]
  • [Cites] Biol Rev Camb Philos Soc. 1998 Aug;73(3):203-66 [9809012.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1446-53 [9834272.001]
  • [Cites] Br J Biomed Sci. 1998 Sep;55(3):172-5 [10367400.001]
  • [Cites] Arch Intern Med. 1999 Jul 12;159(13):1473-80 [10399899.001]
  • [Cites] Emerg Infect Dis. 1999 Jul-Aug;5(4):585-8 [10458970.001]
  • [Cites] Transplantation. 1999 Sep 15;68(5):699-707 [10507491.001]
  • [Cites] J Med Assoc Thai. 1999 Jul;82(7):654-9 [10511766.001]
  • [Cites] Gastroenterology. 1956 Feb;30(2):294-6 [13294318.001]
  • [Cites] Vet Parasitol. 2004 Dec 9;126(1-2):121-44 [15567582.001]
  • [Cites] J Infect Dis. 2005 Jan 1;191(1):11-9 [15592997.001]
  • [Cites] Jpn J Infect Dis. 2004 Dec;57(6):268-70 [15623953.001]
  • [Cites] Curr Opin Infect Dis. 2004 Dec;17(6):557-64 [15640710.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 2004 Sep;35(3):705-10 [15689092.001]
  • [Cites] Epidemiol Infect. 2005 Feb;133(1):23-7 [15724706.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):409-15 [15738369.001]
  • [Cites] Korean J Parasitol. 2005 Mar;43(1):1-5 [15793352.001]
  • [Cites] Parasitol Res. 2005 Apr;96(1):57-61 [15772866.001]
  • [Cites] Indian J Med Microbiol. 2005 Apr;23(2):80-91 [15928435.001]
  • [Cites] J Clin Microbiol. 2005 Jun;43(6):2718-23 [15956388.001]
  • [Cites] Parasite. 2005 Jun;12(2):165-70 [15991830.001]
  • [Cites] Int J STD AIDS. 2005 Jul;16(7):515-7 [16004637.001]
  • [Cites] Int J Infect Dis. 2001;5(4):192-8 [11953215.001]
  • [Cites] Braz J Infect Dis. 2002 Apr;6(2):97-9 [11980611.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1715-8 [11980948.001]
  • [Cites] Mod Pathol. 2002 May;15(5):577-83 [12011264.001]
  • [Cites] Natl Med J India. 2002 Mar-Apr;15(2):72-4 [12044119.001]
  • [Cites] Scand J Infect Dis. 2002;34(11):859-62 [12578164.001]
  • [Cites] Clin Microbiol Infect. 2003 Feb;9(2):110-3 [12588330.001]
  • [Cites] Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):241-4 [12619434.001]
  • [Cites] J Hepatol. 2003 May;38(5):688-91 [12713884.001]
  • [Cites] Bull World Health Organ. 2003;81(3):197-204 [12764516.001]
  • [Cites] J Clin Microbiol. 2006 Sep;44(9):3196-200 [16954247.001]
  • [Cites] Vet Parasitol. 2006 Oct 10;141(1-2):30-41 [16797126.001]
  • [Cites] AIDS Patient Care STDS. 2006 Sep;20(9):606-11 [16987046.001]
  • [Cites] Hemodial Int. 2006 Oct;10(4):375-9 [17014515.001]
  • [Cites] Jpn J Infect Dis. 2006 Oct;59(5):306-10 [17060696.001]
  • [Cites] PLoS Med. 2006 Nov;3(11):e442 [17132052.001]
  • [Cites] Appl Environ Microbiol. 2006 Dec;72(12):7548-53 [17028234.001]
  • [Cites] J Parasitol. 2006 Oct;92(5):1081-7 [17152954.001]
  • [Cites] J Eukaryot Microbiol. 2006;53 Suppl 1:S172-3 [17169049.001]
  • [Cites] J Eukaryot Microbiol. 2006;53 Suppl 1:S22-3 [17169056.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Jan 1;44(1):6-13 [17003690.001]
  • [Cites] Clin Infect Dis. 2007 Feb 1;44(3):466-7 [17205465.001]
  • [Cites] Pediatr Transplant. 2007 Feb;11(1):94-100 [17239130.001]
  • [Cites] Int J Food Microbiol. 2005 Aug 25;103(2):207-27 [16083823.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1390-4 [16105126.001]
  • [Cites] Chemotherapy. 2005 Jul;51(4):193-6 [16006765.001]
  • [Cites] Curr Opin Infect Dis. 2005 Oct;18(5):427-35 [16148530.001]
  • [Cites] Parasitol Res. 2005 Oct;97(4):270-3 [16001279.001]
  • [Cites] J Health Popul Nutr. 2005 Sep;23(3):292-5 [16262027.001]
  • [Cites] Vet Rec. 2005 Nov 12;157(20):623-7 [16284331.001]
  • [Cites] Rev Inst Med Trop Sao Paulo. 2005 Sep-Oct;47(5):301-2 [16302115.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):701-3 [16261304.001]
  • [Cites] Arch Med Res. 2006 Feb;37(2):266-9 [16380329.001]
  • [Cites] J Clin Microbiol. 2006 Jan;44(1):232-5 [16390978.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jan;74(1):162-4 [16407362.001]
  • [Cites] Trends Parasitol. 2006 Feb;22(2):92-6 [16380293.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2006 Feb;25(2):112-5 [16447062.001]
  • [Cites] BMC Infect Dis. 2006;6:39 [16509972.001]
  • [Cites] Int J Infect Dis. 2006 May;10(3):255-61 [16469517.001]
  • [Cites] Trends Parasitol. 2006 May;22(5):203-8 [16545611.001]
  • [Cites] Int J Parasitol. 2005 Jan;35(1):57-62 [15619516.001]
  • [Cites] Lancet. 2006 May 27;367(9524):1747-57 [16731270.001]
  • [Cites] Am J Trop Med Hyg. 2006 Jun;74(6):1016-9 [16760513.001]
  • [Cites] Clin Microbiol Infect. 2006 Jul;12(7):656-9 [16774562.001]
  • [Cites] J Pediatr Surg. 2006 Aug;41(8):1489-91 [16863863.001]
  • [Cites] HIV Med. 2007 Mar;8(2):124-30 [17352769.001]
  • [Cites] Am J Trop Med Hyg. 2007 Mar;76(3):549-52 [17360882.001]
  • [Cites] J Water Health. 2007 Mar;5(1):1-38 [17402277.001]
  • [Cites] Med J Aust. 2007 Apr 16;186(8):412-6 [17437396.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2007 May;26(5):311-23 [17447091.001]
  • [Cites] Jpn J Infect Dis. 2007 May;60(2-3):76-81 [